書籍詳細

[I] 癌悪液質の成因と研究の変遷

P.25 掲載の参考文献

• 1) 漆崎一朗:腫瘍C. 悪液質, 新内科学体系4. 病因論. 中山書店, 東京, 1977, pp. 308-326

• 2) Greenstein, J. P.:Biochemistry of Cancer. 2nd ed. Acad. Press N. Y., 1954

• 3) La Page, G. A. et al.:Growth of carcinoma implants in fed and fasted rats. Cancer Res. 12:153-157, 1952

• 4) Nakahara, W. and Fukuoka, F.:Toxohormone, a characteristic toxic substance produced by cancer tissue. Gann 40:45-69, 1949

• 5) Carswell, E. J., Old, L. J. et al.:An endotoxin-induced serum factors that cause necrosis of tumors. Proc. Natl. Acad. Sci. USA 72:3666-3670, 1975

• 6) Beutler, B. and Cerami, A.:Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986
  pubmed

• 7) 漆崎一朗, 石川邦嗣, 石谷邦彦:神経・内分泌・免疫相関からみた癌のBRM療法-QOL改善の意味するもの. Biotherapy 6:1-8, 1992

• 8) 漆崎一朗, 漆崎洋一:癌悪液質の概念と研究の変遷. 癌治療と宿主2:15-24, 1990

• 9) 中川諭:悪液質. 日内会誌43:255-283, 1954

• 10) Kern, A. K and Norton, J. A.:Cancer cachexia. J. Parenteral and Enteral Nutrition 12:286-298, 1988

• 11) DeWys, W. D., Begg, D., Lavin, P. T. et al.:Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69:491-497, 1980

• 12) 螺良英郎:悪液質について. 癌・免疫・栄養3:1-5, 1988

• 13) Wesdorp, R. I. C., Krause, R. and Von Meyenfeldt, M. F.:Cancer cachexia and its nutritional implications. Brit. J. Surg. 70:352-355, 1983

• 14) Theologides, A.:Anorexia producing inter-mediary metabolism. Am. J. Clin. Nutr. 29:552-558,1976

• 15) 小野武年, 西条寿夫:摂食および飲水行動. Clin. Neuroscience 8:388-393, 1990

• 16) Holroyde, C. P. and Reichard, G. A.:Carbo-hydrate metabolism in cancer cachexia. Cancer Treat. Rep. 65:55-59, 1981

• 17) Norton, J. A., Maher, M., Wesley, R. et al.:Glucose intolerance in sarcoma patients. Cancer 54:3022-3027, 1984
  pubmed

• 18) Lundholm, K., Holm, G. and Schersten, T.:Insulin-resistance in patients with cancer. Cancer Res. 38:4665-4676, 1978
  pubmed

• 19) Shaw, J. H. F. and Wolfe, R. R.:Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer. The response to glucose infusion, parenteral feeding, and surgical resection. Surgery 101:181-191, 1986

• 20) Roh, M. S., Ekman, L, Joevanandam, M. et al:Gluconeogenesis in tumor-influenced hepatocytes. Surgery 96:427-434, 1984

• 21) 漆崎一朗:癌悪液質における蛋白代謝異常. 癌・免疫・栄養3:6-10, 1988

• 22) Jeevanandam, M., Lowry, S. F, Horowitz, G, D. et al:Cancer cachexia and protein metabolism. Lancet 2:1423-1426, 1984

• 23) Norton, J. A., Stein, T. P. and Brennan, M. F.:Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. Ann. Surg. 194:123-128, 1981
  pubmed

• 24) Norton, J. A., Shamberger, R., Slein, T. P. et al.:The influence of tumor-bearing on protein metabolism in the rat. J. Surg. Res. 30:456-463, 1981

• 25) Lundholm, K., Bennegard, K., Eden, E. et al.:Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. Cancer Res. 42:4807-4811, 1982
  pubmed

• 26) Warren, R. S., Jeevanandam, M. and Brennan, M. F.:Comparison of hepatic protein synthesis in vivo versus in vitro in the tumor-bearing rat. J. Surg. Res. 42:43-50, 1987

• 27) Lawson, D. H., Richmond, A., Nixon, P. W. et al:Metabolic approaches to cancer cachexia. Ann. Rev. Nutr. 2:277-301, 1982

• 28) Dinarello, D. A.:Interleukin 1. Rev. Infect. Dis. 6:51-95. 1984

• 29) 漆崎一朗:サイトカインと癌治療. ライフサイエンス社, 東京, 1990

• 30) Shaw, J. H. F. and Wolfe, R. R.:Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer. The response to glucose infusion and parenteral feeding. Ann. Surg. 205:368-376, 1987

• 31) Devareaux, D. F., Redgrave, T. G., Tilton, M. et al.:Intolerance to administered lipids in tumor-bearing animals. Surgery 96:414-419, 1984

• 32) Rouzer, C. A. and Cerami, A.:Hypertriglyceridemia assoicated with trypanosoma brucei infection in rabbits.:Role of defective triglyceride removal. Mol. Biochem. Parasitol. 2:31-38, 1980

• 33) Vlassara, H., Spiegel, R. J., Doval, D. S. et al.:Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm. Metabol. Res. 18:698-703, 1986

• 34) Spiegel, R. J., Schaefer, E. J., Magrath, I. T. et al.:Plasma lipid alterations in leukemia and lymphoma. Am. J. Med. 72:775-782, 1982
  pubmed

• 35) Urushizaki, I.:Biological activities of toxohormone. Chemical tumor problems. Jpn. Soc. J. Promot. Sci., edited., 1970, p.191

• 36) Kampschmidt, RF., Schuliz, G. and Mckenzie, P.:Effects of lipopolysaccharides derived from bacteria and tumor tissue on liver catalase activity, plasma iron concentration and organ weights. J. Natl. Cancer Inst. 28:845-851, 1962

• 37) Kampschmldt, R. F. and Upchurch, H. F.:Effect of bacterial contamination tumor on tumor-host relationship. Res. 23:756-761, 1963

• 38) Fukuda, M., Natori, H., Sampi, K. and Urush-izaki, I.:Comparative studies on the biological effect of toxohormone and bacterial lipopolysaccharide II. Change in liver catalase subfraction separated by electro focusing. Tumor Res. 4:57-72, 1969

• 39) 松尾雄志, 西川克三, 堀尾武一:ローダミニサルコーマ中に存在する肝カタラーゼ低下物質について. 日本癌学会総会記事, 1967, p.84

• 40) Urushizaki, I., Fukuda, M., Matsuda, M. et al.:Biological effects of toxohormone on the iron metabolism of rats. Tumor Res. 4:73-91, 1969

• 41) Suda, M., Tanaka, T., Sue, F. et al.:De-differentiation of sugar metabolism in the liver of tumor-bearing rats. Gann Monograph 1:127-141, 1966

• 42) Borai, B. and DeWye, W.:Assay for presence of anorexic substance in urine of cancer patients. Proc. Am. Assoc. Cancer Res. 21:378, 1980

• 43) Knoll, J. and Satietin, A.:A highly potent anorexigenic substance in human serum. Physiol. Behav. 23:497-502, 1979

• 44) Reichelt, K. L., Foss, I., Trygstol, O. et al.:Humoral control of appetite II. Purification and characterization of an anorexigenic peptide from human urine. Neuroscience 3:1207-1217, 1978

• 45) Norton, J. A., Moley, J. F. , Green, M. V. et al:Parabiotic transfer of cancer anorexia/cachexia in male rats. Cancer Res. 45:5547-5552, 1985
  pubmed

• 46) Moody, T. W., Pert, C. B., Gazdar, A. P. et al.:High level of intracellular bombesin characterize human small cell lung carcinoma. Science 214:1246-1248, 1981

• 47) Krause, R., Humphney, C., Von Megerfeldt, M. et al.:A central mechanism for anorexia in cancer.:A hypothesis. Cancer Treat. Rep. 65 (Suppl. 5):15-23, 1981

• 48) Kawakami, M. and Cerami, A.:Studies of endotoxin-induced decrease in lipoprotein lipase activity. J. Exp. Med. 154:631-639,1981
  pubmed

• 49) Beutler, B., Greenwold, D., Hulmes, J. D. et al.:Identity of tumor necrosis factor and the macrophage-secreted factor, cachectin. Nature 316:552-534, 1985

• 50) Tracey, K. J., Wei, H., Manogue, K. R. et al:Cachectin/TNF induces cachexia, anemia and inflammation. J. Exp. Med. 167:1211-1227, 1988
  pubmed

• 51) Stovroff, M. C., Fraker, D. L, Swedenborg, J. A. et al.:Cachectin/TNF:A possible mediator of cancer anorexia in the rat. Cancer Res. 48:4567-4572, 1988
  pubmed

• 52) Beutler, B. A. and Cerami, A.:Recombinant IL-1 suppresses lipoprotein lipase activity in 3T3 cells. J. Immunol. 135:3969-3991, 1985
  pubmed

• 53) Lonnroth, C., Moldawer, L. L., Gelin, J. et al.:Tumor necrosis facter-a and interleukin-1a production in cachectic, tumor-bearing mice. Int. J. Cancer 46:889-896, 1990

• 54) Langstein, H. N., Doherty, G. M., Fraker, D. L. et al.:The roles ofγ-interferon and TNFa in an experimental rat model of cancer cachexia. Cancer Res. 51:2302-2306, 1991

• 55) Brouckaert, P., Spriggs, D. R., Dematri, G. et al.:Circulating interleukin 6 during a continuous infusion of tumor necrosis factor and interferon γ. J. Exp. Med. 169:2257-2262, 1989

• 56) Moldawer, L. L., Georgieff, M. and Lundholm, K.:Interleukin 1, tumor necrosis factor-alpha (cachectin) and the pathegenesis of cancer cachexia. Clin. Physiol. 7:263-274, 1987

• 57) Last-Barrey, K., Homor, C. A., Foanes, R. B. et al.:Synergistic and overlapping activities of tumor necrosis factor a and IL-1. J. Immunol. 141:527-530, 1988

• 58) Gelin, J., Moldawer, L. L., Lonnroth, C. et al.:Role of endogenous tumor necrosis factor a and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 51:415-421, 1991
  pubmed

• 59) 川上正舒:癌悪液質と cachectin. 癌治療と宿主 2:43-51, 1990

[II] 癌悪液質の病態

P.35 掲載の参考文献

• 1) 標葉隆三郎, 西平哲郎, 森昌造:進行・末期癌患者の栄養管理. 癌治療と宿主 1:59-64, 1989

• 2) 標葉隆三郎, 西平哲郎, 森昌造:癌悪液質と栄養管理. 癌治療と宿主 2:71-76, 1990

• 3) Mider, G. B.:Some Aspects of nitrogen and energy metabolism in cancerous subjects:A review. Cancer Res. 11:821, 1951
  pubmed

• 4) Kern, K. A. and Norton, J. A.:Cancer cachexia. JPEN 12:286-298, 1988
  pubmed

• 5) Wendrop, R. I. C., Krause, R. and von Meyenfeldt, M. F:Cancer cachexia and its nutritional implications. Br. J. Surg. 70:352-355, 1983

• 6) Pisters, P. W. T. and Brennan, M. F.:Amino acid metabolism in human cancer cachexia. Annu. Rev. Nutr. 10:107-132,1990

• 7) Landel, A. M., Hammond, W. G. and Meguid, M. M.:Aspects of amino acid and protein metabolism in cancer-bearing states. Cancer 55:230-237, 1985
  pubmed

• 8) Ogilvie, G. K. and Vail, D. M.:Nutrition and cancer recent developments. Veterinary clinics of north america. Small Animal Practice 20:969-985, 1990
  pubmed

• 9) Shineha, R., Nishihira, T., Sekine, Y. et al.:Biochemical characteristics of human esophageal carcinoma cell line. Esophageal cancer, ed. by Kasai, M., Excerpta Medica, Tokyo, 1986, pp.45-48

• 10) 佐藤清美:アイソザイムのガン胎児性変異. 特にグリコーゲンホスホリラーゼについて. 生化学 49:1091-1119, 1977

• 11) Hyltander, A., Warnold, I., Eden, E. et al.:Effects on whole body protein synthesis after institution of intravenous nutrition in cancer and non-cancer patients who lose weight. Eur. J. Cancer 27:16-21, 1991
  pubmed

• 12) Lundholm, K., Bylund, A-C., Holm, J. et al.:Skeltal muscle metabolism in patients with malignant tumor. Eur. J. Cancer 12:465-473, 1976

• 13) Karlberg, H. I., Kern, K. A. and Fischer, J. E.:Albumin turnover in sarcoma-bearing rats in relation to cancer anorexia. Am. J. Surg. 145:95-101, 1983
  pubmed

• 14) Shaw, J. H., Humberstone, D. A., Douglas, R. G. et al.:Leucine kinetics in patients with benign disease, non-weight-losing cancer, and cancer cachexia:Studies at the whole-body and tissue level and the response to nutritional support. Surgery 109:37-50, 1991
  pubmed

• 15) Sitges-Serra, A., Arcas, G., Guirao, X. et al.:Extracellular fluid expansion during parenteral refeeding. Clinical Nutrition 11:63-68, 1992
  pubmed

• 16) Tracy, K. J. and Cerami, A.:Tumor necrosis factor and regulation of metabolism in infection:role of systemic versus tissue levels. Pro. Soc. Exp. Bio. Med. 200:233-239, 1992

• 17) Hoshino, E., Pichard, C., Greenwood, C. E. et al.:Body composition and metabolic rate in rat during a continuous infusion of cachectin. Am. J. Phisiol. 260:F 27-F 36, 1991

• 18) Brennan, M. F.:Total parenteral nutrition in the cancer patient. New Engl. J. Med. 305:375-382, 1981
  pubmed

• 19) Armstrong, M. D. and Stave, U.:A study of plasma free amino acid levels. III. Variations during growth and aging. Metabolism 22:571-578, 1973

• 20) Aoki, T. T., Muller, W. A., Brennan, M. F. et al.:Blood cell and plasma amino acid levels across forearm muscle during a protein meal. Diabetes 22:768-775, 1973
  pubmed

• 21) Norton, J. A., Gorschboth, C. M., Wesley, R. A. et al.:Fasting plasma amino acid levels in cancer patients. Cancer 56:1181-1186, 1985
  pubmed

P.39 掲載の参考文献

• 1) Yamanaka, H., Nishi, M., Hioki, K. et al.:Preoperative nutritional assessment to predict postoperative complication in gastric cancer patients. JPEN 13:286-291, 1989
  pubmed

• 2) 山中英治, 山本政勝:臨床栄養の最前線-悪性腫瘍. 栄養-評価と治療 7:76-81, 1990

• 3) Kern, K. A. and Norton, J. A.:Cancer cachexia. JPEN 12:286-298, 1988
  pubmed

• 4) 今井圓祐, 野口民夫, 田中武彦:癌細胞の代謝系の変動-癌細胞における酵素偏奇について. 栄養-評価と治療 9:135-141, 1992

• 5) Eden, E., Edstrom, S., Bebbegard, K. et al.:Glycerol dynamics in weight-losing cancer patients. Surgery 97:176-184, 1985

• 6) 辻仲利政, 城戸良弘, 森武貞:特殊な病態の栄養管理-進行癌・末期癌患者.消化器外科 15'647-656, 1992

• 7) Vlassara, H., Spiegel, R. J., Doval, D. S. et al.:Reduced plasma lipoprotein lipase activity in patients with malignancy-associated weight loss. Horm. Metabol. Res. 18:698-703, 1986

• 8) Beutler, B. and Cerami, A.:Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986
  pubmed

• 9) 玉熊正悦, 小野聡:癌悪液質とカケクチン. 医学のあゆみ 149:371-373, 1989
  Medical*Online

• 10) 川上正舒:TNF(腫瘍壊死因子). 治療学 24:61-64, 1990

• 11) 日置紘士郎, 山中英治, 山本政勝:腫瘍免疫の立場からみた栄養. Karkinos 3:899-904, 1990

• 12) Kassiandes, C. and Kew, M. C.:The clinical manifestations and natural history of hepatocellular carcinoma. Gastroenterol. Clin. North Am. 16:553-561, 1987

• 13) 焦昇, 平岡久豊, 松沢佑次:肝疾患と高脂血症. 日本臨牀 48:2585-2592, 1990
  Medical*Online

• 14) Siperstein, M. D. and Fagan, V. M.:Deletion of cholesterol-negative feedback system in liver tumors. Cancer Res. 24:1108-1115, 1964
  pubmed

• 15) Danilewits, M. D.:Automous cholesterol biosynthesis in murine hepatoma. A receptor defect with normal coated pits. Cancer 54:1562-1568, 1984

• 16) Reddy, B. S., Burill, C. and Rigotty, J.:Effect of diets high in omega-3 and omega-6 fatty acids on initiation and postinitiation stages of colon carcinogenesis. Cancer Res. 51:487-491, 1991
  pubmed

• 17) 赤毛義実, 竹山廣光, 由良二郎:脂肪と制癌効果. 栄養-評価と治療 9:175-180, 1992

• 18) 林裕造, 吉村博之:食物, 栄養と癌. Karkinos 3:891-897, 1990

• 19) Paulette, M.:Potential role of platelets in the pathogenesis of tumor metastasis. Blood 63:55-63, 1984

• 20) Ota, D. M., Copeland, E. N., Corriere, J. N. et al.:The effect of a 10% soybean oil-emulsion on lymphocyte transformation. JPEN 2:112-115, 1978

• 21) Whitehead, R. H., Young, G. P. and Bhathal, P. S.:Effects of short chain fatty acid on a new human colon carcinoma cell line (LIM1215). Gut 27:1457-1463, 1986

• 22) Kripke, S. A., Fox, A. D., Berman, J. M. et al.:Stimulation of intestinal mucosal growth with intracolonic infusion of short chain fatty acids. JPEN 13:109-116, 1989
  pubmed

• 23) 武藤輝一, 松原要一, 佐藤信昭ほか:栄養代謝を応用した癌治療. Karkinos 3:913-920, 1990

• 24) 平松義文, 中根恭司, 日置絋士郎ほか:静脈栄養-脂肪乳剤の種類と特徴. 日本臨牀 49:125-129, 1991

• 25) 日置紘士郎:新組成脂肪乳剤開発への動向-MCT 配合脂肪剤の可能性と問題点. 医学のあゆみ 149:374-377, 1989

P.49 掲載の参考文献

• 1) 和田武雄, 上條桂一, 斉藤昭光:悪液質. 癌と化学療法 7:387-395, 1980

• 2) 谷内昭, 上條桂一:低栄養・悪液質. 綜合臨床 39 (増):1097-1103, 1990

• 3) Glickman, A. S. and Rawson, R. W.:Diabetes and altered carbohydrate metabolism in patients with cancer. Cancer 9:1127-1134, 1956

• 4) Coyle, P., Rofe, A. M., Bourgeois, C. S. et al.:Biochemical manifestations of a rat mammary adenocarcinoma-producing cachexia. Immunol. Cell Biol. 68:147-153, 1990
  pubmed

• 5) Paggi, M. G., Fanciulli, M., Garlo, C. D. et al.:Glucose utilization by tumo cells:a post-traslational modification of mitochondrial hexokinase may play a regulatory role. Biocem. Biophys. Res. Comm. 178:648-655, 1991

• 6) Holroyde, C. P., Skutches, C. L., Boden, G. et al.:Glucose metabolism in cachectic patients with colorectal cancer. Cancer Res. 44:5910-5913, 1984
  pubmed

• 7) Mulligan, H. D. and Tisdale, M. J.:Metabolic substrate utilaization by tumour and host tissues in cancer cachexia. Biochem. J. 277:321-326, 1991
  pubmed

• 8) Arbeit, J. M., Burt, M. E., Rubinstein, L. V. et al:Glucose metabolism and the percentage of glucose derived from alanine:response to exogeneous glucose influsion in tumour-bearing and non-tumour bearing rats.Cancer Res. 42:4936-4943, 1982

• 9) Copeland, G. P., Al-Sumidaie, A. M., Leinster, S. J. et al.:Glucose metabolism in patients with gastrointestinal malignancy but without excessive weight loss. Eur. J. Sur. Oncol. 13:11-16, 1987

• 10) Holroyde, C. P., Gabuzda, T. G., Putman, R. C. et al.:Altered glucose metabolism in metastatic carcinoma. Cancer Res. 35:3710-3714, 1975

• 11) Cersosimo, F., Pisters, P. W. T., Pesol, G. et al.:The effect of graded dose of insulin on peripheral glucose uptake and lactate release in cancer cachexia. Surgery 109:459-467, 1991

• 12) Schein, P. P., Kisner, D., Haller, D. et al.:Cachexia of malignancy, potential role of insulin in nutritional management. Cancer 43:2070-2076, 1979

• 13) Byerley, L. O., Heber, D., Bergman, R. N. et al.:Insulin action and metabolism in patients with head and neck cancer. Cancer 67:2900-2906, 1991
  pubmed

• 14) Lundholm, K., Holm, G. and Schersten, T.:Insulin resistance in patients with cancer. Cancer Res. 38:4665-4670, 1978
  pubmed

• 15) 上條桂一, 斎藤定三, 佐藤美也子ほか:癌患者における内分泌環境異常に関する基礎的・臨床的研究. 癌と化学療法 17 (Part II):494-499, 1990

• 16) Kamijo, K., Saito, A., Yachi, A. et al.:Growth hormone response to thyrotropin-releasing hormone in cancer patients. Endocrinol Jpn. 27:451-455, 1980
  pubmed

• 17) 川崎君王, 上條桂一:癌患者における経口ブドウ糖負荷試験時の血清成長ホルモン (GH) の paradoxical response. 札幌医誌 58:331-342, 1989

• 18) Kamijo, K., Kawasaki, K., Sato, M. et al.:Effect of thyrotropin releasing hormone (GH), TSH and growth hormone releasing hormone (GHRH) concentrations in cancer patients. Endocrinol. Jpn. 35:827-831,1988
  pubmed

• 19) 上條桂一, 川崎君王, 佐藤美也子ほか:肝細胞癌におけるGHの分泌異常と耐糖能異常との関係に関する臨床的研究. 癌の臨床 35'775-779, 1989
  Medical*Online

• 20) Kamijo, K., Kato, T., Kawasaki, K. et al.:Low T3 syndrome in cancer patients in relation to weight loss, intravenous hyper-alimentation therapy and age. Endocrinol. Jpn.:33:125-131, 1986

• 21) 上條桂一, 佐藤美也子, 川崎君王ほか:高齢者における甲状腺機能異常の病態生理学的研究. 日本老年医誌 24:538-543, 1987

P.61 掲載の参考文献

• 1) Nakahara, W. and Fukuoka, F.:Toxohormone:a characteristic toxic substance produced by cancer tissue. Gann 40:45-69, 1949

• 2) Kawakami, M. and Cerami, A.:Studies of endotoxin induced decrease in lipoprotein lipase activity. J. Exp. Med. 154:631-639, 1981
  pubmed

• 3) Beutler, B. and Cerami, A.:Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986
  pubmed

• 4) Svaninger, G., Lundberg, P. A. and Lundholm, K.:Thyroid hormones in experimental cancer cachexia. JNCI 77:555-561, 1986
  pubmed

• 5) Siddiqui, R. A. and Williams, J. F.:Tentative identification of the toxohormones of cancer cachexia:Roles of vasopressin, prostaglandin E2 and cachectin-TNF. Bioch. Intern. 20:787-797, 1990

• 6) Mitchell, L. A. and Norton, L. W.:Effect of cancer plasma on skeletal muscle metabolism. J. Surg. Res. 47:423-426, 1989
  pubmed

• 7) Civilli, M., Agradi, E., Bozzetti, F. et al.:Effect of plasma from cancer patients on rat skeletal muscle protein degradation and PGE2 release in vitro. Pharmacol. Res. 22:87-95, 1990

• 8) Theologides, A.:The anorexia-cachexia syndrome; A new hypothesis. Ann. NY Acad. Sci. 230:14-22, 1974
  pubmed

• 9) Russell, D. M., Shike, M., Marliss, E. B. et al.:Effect of total parenteral nutrition and chemotherapy on metabolic derangements in small cell lung cancer. Cancer Res. 44:1706-1711, 1884

• 10) Lindmark, L., Kennegrard, K., Ekman, E. L. et al.:Resting energy expenditure in malnurished patients with and without cancer. Gastroenterol. 87:402-408, 1984

• 11) 日置紘士郎, 山中英治, 平松義文ほか:癌悪液質と栄養. "癌とQuality of Life"漆崎―朗編, ライフサイエンス社, 東京, 1991, pp.211-220

• 12) Beutler, B. and Cerami, A.:Cachectin:More than a tumor necrosis factor. New Engl. J. Med. 316:379-385, 1987
  pubmed

• 13) Grunfeld, C. and Feingold, K. R.:The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3:143-158, 1991
  pubmed

• 14) Patton, J. S., Shepard, H. M., Wilking, H. et al.:Interferons and tumor necrosis factor have similar catabolic effects on 3T3-L1 cells. Proc. Natl. Acad. Sci USA 83:8313-8317, 1986
  pubmed

• 15) Beutler, B. and Cerami, A.:Recombinant interleukin-1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J. Immunol. 135:3969-3971, 1985
  pubmed

• 16) Granfeld, C. and Feingold, K. R.:Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. New Engl. J. Med. 327:329-337, 1992

• 17) 平松義文, 山本政勝, 中根恭司ほか:癌患者の栄養管理. 癌患者と対症療法 1:83-89, 1989

• 18) 上條桂一, 谷内昭:癌患者における神経内分泌異常. Biotherapy 6:1024-1031, 1992

• 19) 川上正舒, 早田邦康:癌悪液質とサイトカイン-TNFと代謝-. Biotherapy 6:1230-1236, 1992

• 20) 網野信行, 館純子:内分泌疾患以外の内科疾患における血中ホルモンの異常値. 内科 61:251-256, 1988

• 21) Knapp, M. L., Al-Sheibani, S., Riches, P. G. et al.:Hormonal factors associated with weight loss in patients with advanced breast cancer. Ann. Clin. Biochem. 28:480-486, 1991
  pubmed

• 22) Schauer, R. J.:Tumor host relations II. Influence of tumor extent and tumor site on plasma cortisol of patients with malignant diseases. J. Cancer Res. Clin. Oncol. 93:287-293, 1979

• 23) Drott, C., Svaninger, G. and Ludholm, K.:Increased urinary excretion of cortisol and catecholamins in malnurished cancer patients. Ann. Surg. 208:645-650, 1988

• 24) 上條桂一, 斎藤定三, 佐藤美也子ほか:癌患者における内分泌環境異常に関する基礎的臨床的研究. 癌と化学療法 17-II:494-499, 1990

• 25) Yamamoto, M., Ariyoshi, Y. and Matsui, N.:The serum concentrations of unbound, transcortin bound and albumin bound cortisol in patients with dysproteinemia. Endocrinol. Jpn. 29:639-646, 1982
  pubmed

• 26) Darling, G., Goldstein, D. S., Stull, R. et al.:Tumor necrosis factor:immune endocrine interaction. Surgery 106:1155-1160, 1989
  pubmed

• 27) Imura, H., Fukata, J. and Mori, T.:Cytokines and endocrine function:an interaction between the immune and neuroendocrine systems. Clin. Endocrinol. 35:107-115, 1991
  pubmed

• 28) 星野孝:サイトカインと神経内分泌系-特に相互関係と臨床的意義について. 消化器癌2:419-433 1992

• 29) 漆崎一朗:サイトカインの神経・内分泌・免疫相関. Biotherapy 6:1178-1187, 1992

• 30) Besedovsky, H., DelRay, A., Sorkin, E. et al.:Immunoregulatory feedback between interleukin 1 and glucocorticoid hormones. Science 233:652-654, 1986

• 31) Smith, L. C., Brown, S. L. and Blalock, J. E.:Interleukin-2 induction of ACTH secretion:presence of an interleukin-2 receptor a-chain-like molecle on pituitary cells. J. Neuroimmunol. 21:249-254, 1989

• 32) Blalock, J. E. and Harp, C.:Interferon and adrenocorticotropic hormone induction of steroidogenesis melanogenesis and antiviral. activity. Arch. Virol. 67:45-49, 1981
  pubmed

• 33) Naito, Y., Fukata, J., Tominaga, T. et al.:Adrenocorticotropic hormone-releasing activities of interleukins in homologous in vivo system. Biochem. Biophys. Res. Commun. 164:1262-1267, 1989
  pubmed

• 34) Naito, Y., Fukata, J., Shindo, K. et al.:Effects of interleukins on plasma arginine vasopressin and oxytocin levels in conscious, freely-moving rats. Biochem. Biophys. Res. Commun. 174:1185-1195, 1991

• 35) Fukata, J., Usui, T., Naitoh, Y. et al.:Effects of recombinant human interleukin-1a,-1B,-2 and-6 on ACTH synthesis and release in the mouse pituitary tumor cell line AtT-20. J. Endocrinol. 122:33-39, 1989

• 36) 深田順一, 井村裕夫:サイトカインの神経内分泌への効果. Biotherapy 6:1032-1040, 1992

• 37) Sapolsky, R., Rivier, C. and Yamamoto, G.:Interleukin 1 stimulates the secretion of hypothalamic corticotropin releasing factor. Science 238:522-524, 1987

• 38) Sharp, B. M., Matta, S. G., Peterson, P. K. et al.:Tumor necrosis factor-a is a potent ACTH secretogogne:Comparison with interleukin-1B. Endocrinol. 124:3131-3133, 1989

• 39) Naito, Y., Fukata, J., Nakaishi, S. et al.:Chronic effects of recombinant human interleukin-1B on hypothalamus, antenior pituitary and adrenal glands in rat. Neuroendocrinol. 51:637-641, 1990

• 40) Lissoni, P., Barni, S., Rovelli, F. et al.:Neuroendocrine effects of subcutaneous interleukin-2 injection in cancer patients. Tumori 77:212-215, 1991
  pubmed

• 41) Navarra, P., Tsagarakis, S., Faria, M. S. et al:Interleukin-1 and-6 stimulate the release of corticotropin-releasing hormone-41 from rat hypothalamus in vitro via the eicosanoid cyclooxygenase pathway. Endocrinol. 128:37-44, 1990

• 42) Yamaguchi, M., Sakata, M., Matsuzaki, N. et al.:Induction by TNF-a of rapid release of immunoreactive and bioactive luteinizing hormone from rat pituitary cells in vitro. Neuroendocrinol. 52:468-472, 1990

• 43) Tominaga, T., Fukata, J., Naito, Y. et al.:Prostaglandin-dependent in vitro stimulation of adrenocortical steroidogenesis by interleukins. Endocrinol. 128:526-531, 1991

• 44) Tancini, G., Barni. S., Crispino, S. et al:A study of thyroid function in cancer cachexia. Tumori 75:185-188, 1989
  pubmed

• 45) 大庭義人, 対馬敏夫:腫瘍とホルモン. 内科 61:247-250, 1988

• 46) Economoto, T., Sugawa, H., Kosugi, S. et al.:Prolonged-term effects of recombinant human interleukin-1a on mouse thyroid function. Endocrinol. 127:2322-2327, 1990

• 47) Scarborough, D. E., Lee, S. L., Dinarello, C. A. et al.:Interleukin-1B stimulates somatostatin biosynthesis in primary culture of fetal rat brain. Endocrinol. 124:549-551, 1989

• 48) Pang, X-P., Hershman, J. M., Mirell, C. J. et al.:Impairment of hypothalamic-pituitary-thyroid function in rats treated with human recombinant TNF-a (cachectin). Endocrinol. 125:76-84,1989

• 49) Ozawa, M., Sato, K., Han, D. C. et al.:Effects of TNF-a/cachectin on thyroid hormone metabolism in mice. Endocrinol. 123:1461-1467, 1988

• 50) Rasmussen, A. K., Bech, K., Feldt-Rasmussen, U. et al.:Interleukin-1 affect the function of cultured human thyroid cells. Allergy 43:435-441, 1988

• 51) Todd, B. D.:Pancreatic carcinoma and low serum testosterone:a correlation secondary to cancer cachexia? Europ. J. Surg. Oncol. 14:199-202, 1988

• 52) Byerley, L. O., Heber, D., Bergman, R. N. et al.:Insulin action and metabolism in patients with head and neck cancer. Cancer 67:2900-2906, 1991
  pubmed

• 53) Cersosimo, E., Pisters, P. W. T., Pesola, G. et al.:The effect of graded doses of insulin in peripheral glucose uptake and lactate release in cancer cachexia. Surgery 109:459-467, 1991

• 54) Burt, M. E., Stein, T. P. and Brennan, M. F.:A controlled, randomized trial evaluating the effects of enteral and parenteral nutrition on protein metabolism in cancer-bearing man. J. Surg. Res. 34:303-314, 1983

• 55) Popp, M. B., Fisher, R. I., Wesley, R. et al.:A prospective randomized study of adjuvant parenteral nutrition in the treatment of advanced diffuse lymphoma:Influence on survival. Surgery 90:195-203, 1981

• 56) Svaninger, G., Isaksson, O. and Lundholm, K.:Growth hormone and experimental cancer cachexia. JNCI 79:1359-1365, 1987
  pubmed

• 57) 上條桂一, 川崎君王, 佐藤美也子ほか:癌患者における内分泌環境異常と抗癌剤の影響. 癌と化学療法 14-II:755-762, 1987

• 58) 飴島慎吾, 星野孝, 宮保進:BRM の神経内分泌機能と QOL への効果-特に OK-432 について. Biotherapy 6:1041-1051, 1992

• 59) Payne, L. C. and Krueger, J. M.:Interactions of cytokines with the hypothalamus-pituitary axis. J. Immunother. 12:171-173, 1992

• 60) Rettori, V., Jurcovicova, J. and McCann, S. M.:Central action of IL-1 in altering the release of TSH, GH, prolactin in the male rat. J. Neurosci. Res. 18:179-183, 1987

• 61) Daynes, R. and Araneo, B. A.:Natural regulators of T cell lymphokine production in vivo. J. Immunother. 12:174-179, 1992
  pubmed

• 62) 川上正舒:TNF(カケクチン)と脂肪酸代謝.Medical Immunol. 14:187-190, 1987

• 63) Sherry, B. A., Gelin, J., Fong, Y. et al.:Anticachectin/TNF-a antibodies attenuate development of cachexia in tumor models. FASEB J. 3:1956-1962, 1989

• 64) Strassmann, G., Fong, M., Kenny, J. S. et al.:Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1681-1684, 1992

• 65) Mori, M., Yamaguchi, K., Honda, S. et al.:Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia inhibitory factor. Cancer Res. 51:6656-6659, 1991
  pubmed

• 66) Schipper, H. and Levitt, M.:Measuring quality of life:Risks and benefits. Cancer Treat. Rep. 69:1115-1123, 1985
  pubmed

• 67) 古江尚:進行癌患者のquality of life, その評価の方法と問題点. 癌と化学療法 14:1-10, 1987
  Medical*Online

• 68) Ganz, P. A., Haskell, C. M., Figlin, R. A. et al.:Estimating the QOL in a clinical trial of patients with metastatic lung cancer using the Karnofsky PS and the functional living index-cancer. Cancer 61:849-856, 1988

• 69) 星野孝:BRMとQOL, 神経内分泌機能による評価の可能性について. Therap. Res. 11:2609-2622, 1990

• 70) 星野孝, 飴島慎吾, 石崎武志ほか:ストレスに対する間脳, 下垂体, 副腎系および下垂体甲状腺系の反応とBRMによる調節, 進行癌患者における検討. 脳と免疫, 1992, (印刷中)

• 71) 石川邦嗣, 岸明彦:QOLからみた癌のBRM療法. Biotherapy 6:1057-1064, 1992

• 72) 星野孝編:JBRM学会公開シンポジウム「BRMと神経・内分泌・免疫系」発表論文集. Biotherapy6特集別刷. 癌と化学療法社, 東京, 1992, pp.1-168

P.70 掲載の参考文献

• 1) 漆崎一朗:腫瘍C, 悪液質. 新内科学大系, 4 巻, 病因論. 中山書店, 1977, p.308

• 2) 漆崎一朗, 漆崎洋一:癌悪液質の概念と研究の変遷. 癌治療と宿主 2:15-24, 1990

• 3) 田口鐵男:癌悪液質における蛋白代謝. 癌治療と宿主 2:27-33, 1990

• 4) 漆崎一朗:癌貧血発生のメカニズム. 癌と化学療法 5:1099-1109, 1978
  Medical*Online

• 5) Beutler, B., Greenwald, D., Hulmes, J. D. et al.:Identity of tumor necrosis factor and the macrophage secreted cachectin. Nature 316:552-554, 1985
  pubmed

• 6) Beutler, B. and Cerami, A.:Cachectin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-588, 1986
  pubmed

• 7) 大澤仲昭:癌悪液質の内分沁的側面. 癌・免疫・栄養 12:11, 1988

• 8) Nakahara, W. and Fukuoka, F.:Toxohormone, a characteristic toxic substance produced by cancer tissue. Gann 40:45-71, 1949.

• 9) 古江尚:担癌過程における宿主免疫機構の低下. 癌と免疫, メディカルレビュー社, 大阪, 1988, pp.36-43

• 10) Tomasi, J. B.:Serum factor which suppress the immune response, regulatory mechanism in lymphocyte activation. Academic Press, New York, 1977, pp.219-248

• 11) 中野達也, 西平哲郎, 森昌造:癌免疫療法と栄養管理. 癌治療と宿主 3:45-52, 1991

• 12) 漆崎一朗:体液性免疫抑制因子の分析. Medicina 19:1026-1029, 1982

• 13) 石塚秀夫, 田中裕:5'-DFURによる癌悪液質の代謝改善. 癌治療と宿主 2:61-68, 1990

• 14) 峠哲哉, 山口佳之, 高山孝弘ほか:サプレッサー因子と免疫抑制細胞との関連性. Biotherapy 3:487-495, 1989

• 15) Toge, T., Yanagawa, E., Nakanishi, K. et al.:Concanavalin-A activated suppressor cell activity in gastric cancer patient. Gann 71:784-789, 1980
  pubmed

• 16) 笠倉新平:サプレッサーT細胞の誘導. 免疫の研究, 同文書院, 東京, 1986, p.125

• 17) 亀田彰:胃がん患者の脾細胞由来免疫抑制因子に関する研究. 広島大医誌 36:33-45, 1988

• 18) 秋山正春:ヒト単球系培養株U937 由来の免疫抑制因子の性状および免疫抑制機序に関する研究. 札幌医誌, 57:291-300, 1988

• 19) Hoagland, J. G., Scoggin, S., Giavazzi, K. et al.:Tumor derived suppressor factors (TDSFs) in normal and neoplastic colon and rectum. J. Surg. Res. 40:467-474, 1986

• 20) Toge, T., Tanada, K., Yajima, K. et al.:Induction of suppressor cell actives in normal lymphocytes by sera from gastric cancer patients. Clin. Exp. Immunol. 54:80-86, 1983

• 21) Silanas-Carmona, M. C., Gery, I., Russel, P. et al.:Mitogen induced suppressor factor from human lymphocytes:Effects in lymphoid and nou. Lymphoid cells, and biophysical properties. Cell Immunol. 71:44-53, 1982

• 22) Greene, W. C., Fleisher, T. A. and Waldman, T. A.:Soluble suppressor supernatants elaborated by concanavalin-A activated human mononuclear cells. I. Characterization of soluble suppressor of T cell proliferation. J. Immunol. 126:1185-1191, 1981

• 23) 峠哲哉, 服部孝雄:がん治療における血漿交換療法の意義. Biotherapy, 2:1019-1028, 1988

P.77 掲載の参考文献

• 1) 早田邦康, 川上正舒:癌悪液質. 臨床検査 35:379-382, 1991

• 2) Tisdale, M. J. and Beck, S. A.:Cancer cachexia. Int. J. Pancreatol. 7:141-150, 1990
  pubmed

• 3) Tisdale, M. J.:Cancer cachexia. Br. J. Cancer 63:337-342, 1991
  pubmed

• 4) 川上正舒, 早田邦康:神経・内分泌・免疫系生体反応へのBRMの効果. 癌悪液質とサイトカイン-TNFと代謝-Biotherapy 6:1230-1236, 1992

• 5) Langstein, H. N. and Norton, J. A.:Mechanisms of cancer cachexia. Hematol. Oncol. Clin. North Am. 5:103-123, 1991
  pubmed

• 6) Nakahara, W. and Fukuoka, F.:Toxohormone:a characteristic toxic substance produced by cancer tissue. Gann 40:45-71, 1949

• 7) 川上正舒:悪性腫瘍の摂食異常. 治療学 21:522-526, 1988

• 8) Theologides, A.:Appetite in anorexia of cancer. Curr. Concepts Nutr. 16:101-124, 1988
  pubmed

• 9) Bernstein, I.L.:Etiology of anorexia in cancer. Cancer 58:1881-1886, 1986
  pubmed

• 10) Kawakami, M. and Cerami, A.:Studies of endotoxin induced decrease in lipoprotein lipase activity. J. Exp. Med. 154:631-639, 1981
  pubmed

• 11) Kawakami, M., Pekala, P. H., Lane, M. D., et al.:A lipoprotein lipase suppression in 3T3-L1 cells by an endotoxin-induced wediator from exudate cells. Proc. Nati. Acad. Sci. USA 79:912-916, 1982

• 12) Kawakami, M., Ikeda, Y., Tradg, N. L. et al.:Studies of conditions and agents that stimulate and inhibit the production of cachectin by macrophages. Proceedings of IUPHR. Paton, W., Ed. Macmillan Press 2:377-384, 1984

• 13) Theologides, A.:Anorexins, asthenins, an cachectins in cancer. Am. J. Med. 81:696-698, 1986
  pubmed

• 14) Beutler, B., Greenwalt, D., Humes, J. D. et al.:Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 316:552-554, 1985

• 15) 川上正舒:カケクチンと TNF. 生化学 59:1244-1247, 1987

• 16) 川上正舒:質疑応答-サイトカインの定義と分類. 医事新報 3531:129-130, 1991

• 17) Pekala, P. H., Kawakami, M., Angus, W. et al.:Selective inhibition of the synthesis of the enzymes for de novo fatty acid biosynthesis by an endotoxin-induced mediator from exudate cells. Proc. Natl. Acad. Sci. USA 80:2743-2747, 1983

• 18) Kawakami, M., Murase, T., Ogawa, H. et al.:Human recombinant TNF suppresses lipoprotein lipase-activity and stimulates lipolysis in 3T3 L1 cells. J. Biochem. 101:331-338, 1987
  pubmed

• 19) Cerami, A., Ikeda, Y., Le Trang, N. te al.:Weight loss assoc-ated with an endotoxin-induced mediator from peritoneal macrophages:the role of cachectin (tumor necrosis factor). Immun. Letter 11:173-177, 1985

• 20) 川上正舒:TNFの生理活性. Medical Immunology 19:681 686, 1990

• 21) Dinarello, C. and Wolff, S. M.:The role of interleukin-1 in disease. N. Eng. J. Med. 328:106-113, 1993

• 22) 中嶋弘一, 平野俊夫:IL-6 の基礎と臨床. 癌と化学療法 18:505-514, 1991
  Medical*Online

• 23) Strassmann, G., Fong, M., Kenney, J. S. et al.:Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1681-1684, 1992
  pubmed

• 24) Strassmann, G., Jacob, C. O., Evans, R. et al.:Mechanism of experimental cancer cachexia. Interaction between monocuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J. Immunol. 148:3674-3678, 1992

• 25) Socher, S. H., Friedman, A. and Marinez, D.:Recombinant human tumor necrosis factor induces acute reduction in food intake and boody weight in mice. J. Exp. Med. 167:1957-1962, 1988

• 26) Hellerstein, M. K., Meydani, N. M., Meydani, M. et al.:Interleukin-1-induced anorexia in the rat. J. Clin. Invest. 84:228-235, 1989

• 27) Kuriyama, K., Hori, T., Mori, T, et al.:Actions of interferon a and interleukin-1B on the glucose-responsive neurons in the ventromedial hypothalamus. Brain Res. Bull. 24:803-810, 1990

• 28) Oomura, Y.:Chemical and neuronal control of feeding motivation. Physiol. Behav. 44:555-560, 1988
  pubmed

• 29) Plata-Slaman, C. R., Oomura, Y. and Kai, Y.:Tumor necrosis factor and interleukin-B suppresion of food intake by direct action in the central nervous system. Brain. Res. 448:106-114, 1988

• 30) Uehara, A., Sekiya, C., Takasugi, Y. et al.:Anorexia induced by interleukin 1:involvement of corticotropin-releasing factor. Am. J. Physiol. 257:R 613-617, 1989

• 31) Chlebowski, R. T. and Heber, D.:Metabolic abnormalities in cancer patients:carbohydrate metabolism. Surg. Clin. North Am. 66:957-968, 1986
  pubmed

• 32) Wolfe, R. R.:Glucose metabolism in sepsis and endotoxicosis. In:Powanda, M. C, Canonico, P. G. (eds) Infection:The Physiologic and metabolic responses of the Host. Elsevier/North-Holland, New York, 1981, pp.214-243

• 33) Warren, R. S., Starnes. F., Gabrilove, J. L. et al.:The acute metabolic effects of tumor necrosis factor administration in humans. Arch. Surg. 122:1396-1400, 1987

• 34) Bagby, G. J., Plessala, K. J., Wilson, L. A. et al.:Glucose kinetics in rats infused with endotoxin-induced monokines or tumor necrosis factor. Circ. Shock 24:111-121, 1988
  pubmed

• 35) Evans, D. A., Jacobs, D. O. and Wilmore, D. W.:Tumor necrosis factor enhances glucose uptake by peripheral tissues. Am. J. Physiol. 257:R 1182-1189, 1989

• 36) Meszaros, K. C., Lang, C. H., Bagby, G. J. et al.:Tumor necrosis factor increases in vivo glucose utilization of macrophage-rich tissues. Biochem. Biophys. Res. Commun. 149:1-6,1987

• 37) Lang, C. H., Dobrescu, C. and Bagby, G.:Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52, 1992
  pubmed

• 38) Lang, C. H., Cobrescu, C. and Meszaros, K.:Insulin-mediated glucose utilization of individual tissues during sepsis. Metabolism 39:1096-1107, 1990

• 39) Cornelius, P., Lee, M. D. and Marlowe, M.:Monokine regulation of glucose transporter mRNA in L6 myotubes. Biochem. Biophys. Res. Commun. 165:429-436, 1986

• 40) Hotamisligil, G. S., Shargill, N. S. and Spegelman, B. M.:Adipose expression of tumor necrosis factor-a:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993

• 41) Tracey, K. J., Lowry, S. F., Fahey III, T. J. et al.:Cachectin/Tumor necrosis factor induces lethal shoch and stress hormone responses in the dog. Surgery, Gynecology and Obstetrics 164:415-422, 1987

• 42) Warren, R. S., Starnes, H. F., Alcock, N. et al.:Hormonal and metabolic response to recombinant human tumor necrosis factor in rat:in vitro and in vivo. Am. J. Physiol. 255:E 206-212, 1988

• 43) Michie, H., Spriggs, D. R., Manogue, K. R. et al.:Tumor necrosis factor and endotoxin induce similar metabolic responses in human beings. Surgery 104:280-286, 1988
  pubmed

• 44) Kawakami,M., Watanabe, N., Ogawa, C. et al.:Specificity in metabolic effects of cachectin/TNF and other related cytokines. Ann. NY. Acad. Sci. 587:339-350, 1990

• 45) Semb, H., Peterson, J., Tavernir, J. et al.:Multiple effects of tumor necrosis factor on lipoprotein lipase in vivo. J. Biol. Chem. 262:8390-8394, 1987
  pubmed

• 46) Grunfeld, Gulli, R., Moser, A. H. et al.:The effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J. Lipid Res. 30:579-585, 1989

• 47) Chajek-Shaul, T., Friedman, G., Stein, O. et al.:Mechanism of the hyperlipidemia induced by tumor necrosis factor administration to rats. Biochim. Biophys. Acta 100:316-324, 1989

• 48) Feingold, K. R., Doerrleer, W., Dinarello, C. A. et al.:Stimulation of lipolysis in cultured fat cells by tumor necrosis factor, interleukin-1, and the interferons is blocked by inhibition of prostaglandin synthesis. Endocrinology 130:10-16, 1992

• 49) Feingold, K. R. and Grunfeld, C.:Tumor necrosis factor-alpha stimulates hepatic lipogenesis in the rat in vivo. J. Clin. Invest. 80:184-190, 1987
  pubmed

• 50) Feingold, K. R., Serio, M. K., Adi, S. et al.:Tumor necrosis factor stimulates hepatic lipid synthesis and secretion. Endocrinology 124:2336-2342, 1989
  pubmed

• 51) Feingold, K. R., Soued, M., Serio, M. K. et al.:Multiple cytokines stimulate hepatic lipid synthesis in vivo. Endocrinology 125:267-274, 1989
  pubmed

• 52) Grunfeld, C., Adi, S., Soued, M. et al.:Search for mediators of the lipogenic effects of tumor necrosis factor:potential role for interleukin 6. Cancer Res. 50:4233-4238, 1990
  pubmed

• 53) Feingold, K. R., Adi, S., Staprans, I. et al.:Diet affects the mechanisms by which TNF stimulates hepatic trigyceride production. Am. J. Physiol. 259:E 177-184, 1990

• 54) Kushner, I.:The phenomenon of the acute phase response. Am. NY. Acad. Sci. 389:39-48, 1982

• 55) O'Donnel, R. F., Clowes, G. H. A., Blackburn, G. L. et al.:Proteolysis associated with a deficit of peripheral energy fuel substrates in septic man. Surgery 80:192-200, 1976

• 56) Hasselgren, P. O., James, J. H., Warner, B. W. et al.:Reduced muscle amino acid uptake in sepsis and the effects in vitro of septic plasma and interleukin-1. Ann. Surg. 100:222-228, 1986

• 57) Starnes, H. F., Warren, R. S., Jeevanandam, M. et al.:Tumor necrosis factor and the acute metabolic response to tissue injury in man. J. Clin. Invest. 82:1321-1325, 1988

• 58) Moldawer, L, Svaninger, G., Gelin, J. et al.:Interleukin-1 and tumor necrosis factor do not regulate protein balance in skeletal muscle. Am. J. ,Physiol. 253:C 766-773, 1987
  pubmed

• 59) Goldberg, A., Kettlehut, L, Furuno, K. et al. Activation of protein breakdown and prostaglandin E2 production in rat skeletal muscle in fever is signaled by a macrophage product distinct from interleukin-1 or other known monokines. J Clin. Invest. 81:1378-1383, 1988
  pubmed

• 60) Mealy, K, van Lanschot, J. J. B., Robinson, B. G. et al.:Are the catabolic effects of tumor necrosis factor mediated by glucocorticoids? Arch. Surg. 125:42-48, 1990

• 61) Starnes, H. F, Warren, R. S., Conti, P. S. et al.:Redistribution of amino acids in rat liver and muscle induced by tumor necrosis factor requires the adrenal response. Surg. Forum 18:41-42, 1987

• 62) Fukusima, R, Saito, H., Taniwaka, K. et al.:Abumrad, N. N. Different roles of IL-1 and TNF on hemodynamics and interorgan amino acid metabolism in awake dogs. Am. J. Physiol. 262:E 275-281, 1992

• 63) Castell. J. V., Gomez-Lechon, M. J., David, M. et al.:Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett. 242:237-239, 1989
  pubmed

• 64) Brenner, D. A., Buck, M., Feitelberg, S. P. et al.:Tumor necrosis factor-a inhibitis albumin gene expression in a murine model of cachexia. J. Clin. Invest. 85:248-255, 1990

• 65) Mackiewicz, A., Speroff, T., Ganapathi, M. K. et al.:Effects of cytokine comibination on acute phase protein production in two human hepatoma cell lines. J. Immuno. 164:3032-3037, 1991

• 66) Sharma, R. J., Macallan, D C., Sedgwick, P. et al.:Kinetics of endotoxin-induced acut-phase protein gene expression and its modulation by TNF-a monoclonal antibody. Am. J. Physiol. 262:R 786-793, 1992

• 67) Kondo, Y., Sato, K., Ueyama, Y. et al.:Serum sialyltransferase and liver catalase activity in cachectic nude mice bearing a human malignant melanoma. Cancer:Res. 41:2912-2916, 1981
  pubmed

• 68) Kawakami, M., Kondo, Y., Imai, Y. et al.:Suppression of lipoprotein lipase in 3T3-L1 cells by a mediator produced by SEKI melanoma, a cachexia-inducing human melanoma cell line. J. Biochem. 109:78-82, 1991
  pubmed

• 69) Mori, M., Yamaguchi, K. and Abe, K.:Purification of a lipoprotein lipase-inhibiting Protein produced by a melanoma cell line associated with a cancer cachexia. ,Biochem. Biophys. Res. Commun. 160:1085-1092, 1989
  pubmed

• 70) 早田邦康, 川上正舒, 柏井昭良ほか:カケクチン (TNF) と外科疾患-敗血症ショックと癌悪液質. 侵襲と免疫 1:15-20, 1991

P.86 掲載の参考文献

• 1) Greenstein, J. P.:Biochemistry of Cancer. (ed. 2), Academic Press, New York, 1954

• 2) Nakahara. W. and Fukuoka, F:A toxic cancer tissue constituent as evidenced by it effect on liver catalase activity. Jpn. J. Med. 1:271, 1948

• 3) Nakahara, W. and Fukuoka, F.:Toxohormone. A characteristic toxic substance produced by cancer tissue. Gann 40:45, 1949

• 4) Kondo, Y. et al.:Cachexia in nude mice bearing a human malignant melanoma. Proc. Second International Workshop on Nude Mice, University of Tokyo Press, 1977, p.441

• 5) Kawakami, M. and Cerami, A.:Studies of endotoxin-induced decrease in lipoprotein lipase activity. J. Exp. Med. 154:631, 1981
  pubmed

• 6) Strassmann, G. et al.:Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1681, 1992
  pubmed

• 7) Mori, M. et al.:Purification of lipoprotein lipase-inhibiting protein produced by a melanoma cell line associated with cancer cachexia. Biochem. Biophys. Res. Commun. 160:1085, 1989
  pubmed

• 8) Gough, N. M. et al.:Molecular cloning and expression of the human homologue of the murine gene encoding myeloid leukemia-inhibitory factor. Proc. Natl. Acad. Sci. USA 85:2623, 1988
  pubmed

• 9) Mori, M., Ueda, M. et al.:Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer:Res. 51:6656, 1991
  pubmed

• 10) Metcalf, D. and Gearing, D. P.:Fatal syndrome in mice engrafted with cells producing high level of the leukemia inhibitory factor. Proc. Natl. Acid. Sci. USA. 86:5948, 1989

• 11) Metcalf, D., Nicola, N. A. and Gearing, D. P.:Effect of injected leukemia inhibitory factor on hematopoietic and other tissues in mice. Blood 76:50, 1990
  pubmed

• 12) Spiegel, R. J. et al.:Plasma lipid alterations in leukemia and lymphoma. Am. J. Med. 72:775, 1982
  pubmed

[III] 癌悪液質の臨床症状と検査成績

P.94 掲載の参考文献

• 1) DeWys, W. D., Begg, D., Lavin, P. T. et al.:Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69:491-497, 1980

• 2) Norton, J. A., Stein, T. P. and Bernnan, M. F.:Whole body protein synthesis and turnover in normal man and malnourished patients with and without known cancer. Ann. Surg. 194:123-128, 1981

• 3) Lundholm, K., Bylund, A. C., Holm, J. et al.:Skeletal muscle metabolism inpatients with malignant tumor. Eur. J. Cancer. 12:465-473, 1976

• 4) Norton, J. R., Shamberger, R., Stein, T. P. et al.:The influence of tumor-bearing on protein metabolism in the rat. J. Surg. Res. 30:456-462, 1981

• 5) Lundholm, K., Bennegard, K., Eden, E. et al.:Efflux of 3-methylhistidine from the leg in cancer patients who experience weight loss. Cancer Res. 42:4807-4811, 1982
  pubmed

• 6) Karlberg, H. I., Kern, K. A. and Fischer, J. E.:Albumin turnover in sarcoma-bearing rats in relation to cancer anorexia. Am. J. Surg. 145:95-101, 1983
  pubmed

• 7) Karlberg, H. I., Ekman, L., Edstrom, S. et al.:Reutilization of amino acid carbons in relation to albumin turnover in non-growing mice with sarcoma. Cancer Res. 42:2284-2288, 1982

• 8) Schaur, R, J., Semmenbrock, H. F. , Schauen-stein, E. et al.:Tumor host relations. I. Increased plasma cortisol in tumor-bearing humans compared with patients with benign surgical diseases. J. Cancer Res. Clin. Oncol. 93:281-285, 1979

• 9) Schworer, C. M. and Mortimoire, G. E:Glucagon-induced autophagy and proteolysis in rat liver:Mediation by selective deprivation of intracellular amino acids. Proc. Natl. Acad. Sci. USA 76:3169-3173, 1979

• 10) Dinarello, D. A.:Interleukin 1. Rev. Infect. Dis. 6:51-95, 1984

• 11) Butler, B. and Cerami, A.:Cachetin and tumor necrosis factor as two sides of the same biological coin. Nature 320:584-588 1986

• 12) Begg, R. W.:Tumor-host relations. Adv. Cancer Res. 5:1-54, 1958
  pubmed

• 13) Shaw, J. H. F. and Wolfe, R. R.:Glucose and urea kinetics in patients advanced gastrointestinal cancer:the response to glocuse infusion, parenteral feeding and surgical resection. Surgery 101:181-191, 1986

• 14) Lundholm, K, Holm, G. and Schersten, T.:Insulin resistance in patients with cancer. Cancer Res. 38:4665-4670, 1978
  pubmed

• 15) Lundholm, K, Bylund, A. C. and Schersten, T.:Glucose tolerance in relation to skeletal muscle enzyme activities in cancer patients. Scand. J. Clin. Lab. Invest. 37:267-272, 1977
  pubmed

• 16) Kralovic, R. C., Zepp, A. and Canedella, R. J.:Studies of the mechanism of carcass fat depletion in experimental cancer. Eur. J. Cancer 13:1071-1079, 1977

• 17) Vlassara, H., Spiegel, R. J., Deva|, D. S. et al.:Reduced plasma lipoprotein lipase activity in the patients with malignancy-associated weight loss. Horm. Metabol. Res. 18:698-703, 1986

• 18) Kawakami, M., Pekela, P. H., Lane, M. D. et al.:Lipoprotein lipase suppression in 3T3-L-cells by an endotoxin-induced mediator from exudate cells. Proc. Natl. Acad. Sci. USA 79:912-916, 1982

• 19) Beck, S. A. and Tisdale, M. J.:Lipid mobilising factors specifically associated with cancer cachexia. Br. J. Cancer 63:846-850,1991
  pubmed

• 20) Morrison, S. D.:Extrahypothalamic mediation of change in feeding behavior induced by growth of Walker 256 carcino-sarcoma in rats. Cancer Res. 41:1710-1714, 1981

• 21) Morrison, S. D.:Feeding response to change in absorbable food fraction during growth of Walker 256 carcino-sarcoma. Cancer Res. 32:968-972, 1972

• 22) Henkin, R. I., Mattes-Kulig, D. and Lynch, R. A.:Taste and smell acuity in patients with cancer. Fed. Proc. 42:550, 1983

• 23) Morrison, S. D.:Limited capacity for motor activity as a cause for declining food intake in cancer. J. Natl. Cancer Inst. 51:1535-1539, 1973

• 24) Zucker, S.:Cancer cell inhibition of erythropoiesis. J. Lab. Clin. Med. 96:770-782, 1980
  pubmed

• 25) 漆崎一朗, 漆崎洋一:癌悪液質の概念と研究の進歩. 癌治療と宿主2:15-24, 1990

• 26) Hyman, G. A.:Anemia in malignant neoplastic disease. J. Chronic Dis. 16:645-666, 1963
  pubmed

• 27) 中啓三, 石川修, 辰田一郎ほか:癌悪液質発症機序に関する研究-貧血誘発物質 (AIS) の産生とその免疫抑制作用について. 産婦進歩41:305-312, 1989

• 28) Goldberg, R. J., Seneff, M., Gore, J. M. et al.:Occult malignant neoplasm in patients with deepvenous thrombosis. Arch. Intern. Med. 147:251-253, 1987

• 29) Verstraet, M. and Vermylen, J.:Thrombosis. Pergamon, Oxford, 1984, p.222

• 30) Falanga, A. and Gordon, S. G.:Purification and characterization of cancer procoagulant:A cystein proteinase from malignant tissue. Biochemistry 24:5558-5567, 1985

• 31) Buchanan, M. R.:Mechanism of pathogenesis of arterial thrombosis:Potential sites of inhibition by therapeutic compounds. Sem. Thromb. Hemostas. 14:33-40, 1988

• 32) 松田保, 小河原緑, 児玉直子ほか:各種疾患における血漿アンチトロンビン (antithrombin III, a2-macroglobulin) の変動. 日血会誌 40:261-266, 1977

• 33) Burt, M. E. and Brennan, M. F:Incidence of hypercalcemia and malignant neoplasm. Arch. Surg. 115:704-707, 1980
  pubmed

• 34) Suva, L. J., Winskow, G. A., Wettenhall, R. E. H. et al.:A parathyroid hormon-related protein implicated in malignant hypercalcemia:Cloning and expression. Science 273:893-896, 1987

• 35) Holmes, E. C:Immune adjuvant therapy in lung cancer. Prog. Exp . Tumor Res. 25:229-241, 1980
  pubmed

• 36) Tamura, K., Shibata, Y., Matsuda, Y. et al.:Isolation and characterization of an immunosuppressive acidic protein from ascitic fluid of cancer patients. Cancer Res. 41:3244-3252, 1981
  pubmed

• 37) Werkmeister, J., Zbroja, R., McCarthy, W. et al.:Detection of an inhibitor of cell division in cultures of tumor cells with immunosuppressive activity in vitro. Clin. Exp. Immunol. 40:168-177, 1980
  pubmed

• 38) Shirakawa, F., Tanaka, Y., Oda, S. et al.:Immunosuppressive factors from adult T-cell leukemia cells. Cancer Res. 46:4458-4462, 1986
  pubmed

• 39) Wrann, M., Bodmer, S., Martin, R. et al.:T cell suppressor factor from human glioblastoma cells is a 12.5-kd protein closely related to transforming growth factor-B. EMBOJ. 6:1633-1636, 1987

[IV] 癌悪液質のPalliative Therapy

P.105 掲載の参考文献

• 1) 世界保健機関編 (武田文和訳):がんの痛みからの解放. WHO方式癌疼痛治療法. 金原出版, 東京, 1987

• 2) WHO:Cancer Pain Relief and Palliative Care. Technical Report Series, No. 804, WHO, Geneva, 1990

• 3) 厚生省・日本医師会編:がん末期医療に関するケアのマニュアル. 末期医療のケア. 中央法規. 東京, 1989

• 4) 武田文和:がんの「いたみ」克服の知恵. 藤田達士. 真興交易, 東京, 1988, p.49

• 5) 厚生省薬務局麻薬課監修:麻薬・向精神薬・覚せい剤管理ハンドブック. 薬業時報社, 東京, 1990

• 6) Hiraga, K.:Current status and future needs in cancer pain management in Japan. Cancer Pain Relief and Quality of Life. Takeda, F. (ed.), WHO Collaborating Center at the Saitama Cancer Center, Saitama, 1992, pp.32-pp.38

• 7) Twycross, R. G. and Lack, S. A. (武田文和訳):末期癌患者の診療マニュアル. 痛みの対策と症状のコントロール. 第2版. 医学書院, 東京, 1991

• 8) 武田文和, 石垣靖子編:癌患者の症状のコントロール. 医学書院, 東京, 1990

• 9) McCaffery, M.:癌の痛みの治療における看護婦の役割. 癌患者と対症療法2:54-62, 1991

• 10) 武田文和:普及しやすくなった癌と除痛法. モダンメディシン18:91-93, 1989

• 11) 武田文和:モルヒネの適切な投与がカギ. モダンメディシン19:99-103, 1990

P.115 掲載の参考文献

• 1) Hyman, G. A.:the anemia of cancer. Am. J. Roentgenol. 79:511-520, 1958

• 2) 中尾喜久, 前川正, 和田武久:癌腫症の貧血とその成因. 臨床血液5 (Suppl.):144-152, 1964

• 3) 漆崎一朗:癌貧血発生のメカニズム. 癌と化学療法5:1099-1109, 1978

• 4) 漆崎一朗:癌性貧血の成因と対策-erythropoietin の臨床応用. 癌治療と宿主3:111-119, 1991

• 5) 名倉新一:癌の合併症対策 2) 癌性貧血. 日本臨牀 47 増刊癌治療学 (下):138-143, 1989

• 6) Urushizaki, I.:Biological activities of toxohormone. W. Nakahara ed. Chemical tumor Problems. Jap. Soc. Promot. Sci. 1970

• 7) 漆崎一朗:サイトカインと癌治療. ライフサイエンス社, 東京, 1989

• 8) 漆崎一朗:癌と貧血. 臨床成人病15:337-843, 1985

• 9) 漆崎一朗, 漆崎洋一, 高後裕:細胞増殖と transferrin receptor. Oncologia 5:109-120, 1983

• 10) Engelmann, B., Grevers, G., Janka, H. U. et al.:Alteration in Na+, K+and Ca2+ transport in erythocytes of patients with carcinomomas of the head and neck.:Possible role of mild anemia and cell age. Clin. Sci 78:315-320, 1990

• 11) 辰田一郎・名河修・中敬三ほか:癌貧血発症機序に関する臨床的基礎的検討. 産婦進歩41:293-313, 1989

• 12) Doweiko, J. P. and Goldberg, M. A.:Erythropoietin therapy in cancer patients. Oncology 5:31-44, 1991
  pubmed

• 13) 浅野茂隆:造血因子の位置づけ. 造血因子1:25-36, 1990

• 14) Beutler, B. and Cerami, A.:Cachectin and tumor necrosis factor as two side of the same biological coin. Nature 320:584-588, 1986

• 15) Broxmeyer, H. E., Williams, D. S., Lu, L. et al.:The suppressive iufluence of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia:Synergism of tumor necrosis factor and interferon-gamma. J. lmmunol. 136:4487-4493, 1986

• 16) Roodman, G. D., Bird, A., Hutzler, D. et al.:Tumor necrosis factor-alpha and hematopoietic progenitors:Effets of tumor necrosis factor on the growth of erythroid progenitors CFU-E and BFU-E and the hematopoietic cell lines K 562, HL60, HEL cells. Exp. Hemat. 151:928-935, 1987

• 17) Johnson, C. S., Chang, M. J. and Furmanski, P.:In vivo hematopoietic effects of tumor necrosis factor-a in normal and erythroleukemic mice:Characterization and therapeutic applications. Blood 72:1875-1883, 1988
  pubmed

• 18) 大田雅嗣:TGF-B の血液系への作用とシグナル伝達. 実験医学8:321-329, 1990

• 19) 斎藤正樹:遺伝子組換えとエリスロポエチン. 医学のあゆみ152:207-210, 1990

• 20) Miyake, T., Kung, C. K. H. and Goldwasser, E:Purification of human erythropoietin. J. Biol. Chem. 252:5558-5564, 1977

• 21) Metcalf, D.:The colony-stimulating factors. Discovery, development, and clinical application. Cancer 65:2185-2195, 1990
  pubmed

• 22) 浦部晶夫:G-CSFの臨床応用. 癌治療と宿主3:129-134, 1991

• 23) 前田隆浩, 朝長万左男:GM-CSFの臨床応用. 癌治療と宿主3:135-144, 1991

• 24) 元吉和夫:M-CSF の臨床応用. 癌治療と宿主3:145-154, 1991

• 25) Bagby, Jr. G. C.:Interleukin-1 and hematopoiesis. Blood Rev. 3:152-161, 1989

• 26) 北村聖:IL-1 の臨床応用. 診断と治療80:1029-1035, 1992

• 27) 漆崎一朗:癌のpalliative therapy. 癌と化学療法社, 東京, 1992

• 28) 山田英雄:エリスロポエチン-最近における研究の進歩. 医薬ジャーナル24:783-792, 1988

• 29) Ward, H. P., Kulkarni, V. and Pisanczyk, M. J.:Serum level of erythropoietin in anemias associated with chronic infection, malignancy and primary hematopoietic disease. J. Clin. Invest. 50:332-335, 1975

• 30) Firat, K. and Banzon, J.:ErythroPoietic effect of plasma from patients with advanced cancer. Cancer Res. 31:1355-1359, 1971

• 31) Zucker, S., Friedman, S. and Lyrik, R. M.:Bone Marrow erythropoiesis in the anemia of infection, inflammation and malignancy. J. Clin. Invest. 53:1132-1138, 1974

• 32) MacManus, M. P., Elder, G. M., Abram, W. P. et al.:Effect of recombinant human erythropoietin on anemia caused by a murine mammary carcinoma. Exp. Hematol. 18:848-852, 1990

• 33) Miller, C. B., Jones. R. J., Plantadost, S. et al.:Decreased erythropoietin response in patients with the anemia of cancer. New Engl. J. Med. 322:1689-1692,1990

• 34) Means. R. T., Olgen, N. J. , Krantz, S. B. et al.:Treatment of the anemia of rheumatoid arthritis with recombinant human erythropoietin:clinical and in vitro study. Arthritis. Rheuma. 32:638-644, 1989

• 35) Clibon, U., Bonewald, L, Caro, J. et al.:Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor a. Exp. Hematol. 18:438-441, 1990
  pubmed

• 36) 0ster, W., Herrmann, F., Gamon, H. et al.:Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. J. Clin. Oncol. 8:956-962, 1990

• 37) Henry, D.:Enythropoietin in the treatment of anemia associated with cisplatin chemotherapy. Biotherapy and Cancer 3:1-7, 1990

• 38) Ludwig, H., Fritz, E., Kotzmann, H. et al.:Erythropoietis treatment of anemia of cancer. Proc. Am. Soc. Clin. Oncol. 9:201, 1990

• 39) Abels, A., Gordon, D., Rose, E. et al.:Efficacy and safety of recombinant human erythropoietin in anemic cancer patients. Proc. Am. Soc. Clin. Oncol. 10:346, 1991

• 40) Miller, C. B., Platanias, L. C., Rotsin, M. J. et al.:A phase I/II trial of erythropoietin in the treatment of chemotherapy-induced anemia in patients with cancer. Proc. Am. Soc. Clin. Oncol. 9:194, 1990

• 41) Platanias, L C. et al.:Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer-patients. J. Clin. Oncol. 9:2021-2026, 1991
  pubmed

• 42) Hoyden, J. T. Hutchins, K., Jagannoth, L. et al.:Recombinant human erythropoietin is effective in correcting the anemia of multiple myeloma. Proc. Am. Soc. Clin. Oncol. 11:367, 1992

• 43) Pedrazzoli, P., Rosti, V., Pondio, L. et al.:Effect of recombinant human erythropoietin of solid tumor and leukemia-derived cell lines. Proc. Am. Soc. Clin. Oncol. 11:124, 1992

• 44) 宇部真明・八木田旭邦・織田一郎ほか:炎症腸炎・消化器癌の貧血に対するrh・エリスロポエチンの臨床応用. Therapeutic Res. 11:232-235, 1990

• 45) 浦部晶夫:癌患者の貧血とエリスロポエチン. Biotherapy 6:933-937, 1992

P.127 掲載の参考文献

• 1) 越川昭三, 中島豊:電解質代謝障害. 日本臨牀 42 (秋期臨時増刊号):1006-1017, 1984

• 2) Berl, T. et al.:Clinical disorders of water metabolism. ,Kidney Int. 10:117-124, 1976
  pubmed

• 3) Berl, T. et al.:Renal and electrolyte disorders. 3rd ed. Schrier R. W., Little Brown, Boston, 1986, pp.44-77

• 4) Tannen, R. L.:Potassium disorders. In:Fluidsand electrolytes. eds. by Kokko, J. P. and Tannen, R. L, W. B. Saunders Co. philadelphia, 1986, p.195-300

• 5) Cogan, M. G:Fluid & electrolytes. In:Physiology & pathophysiology, Prentice Hall International Inc. London, 1991

• 6) 北岡建樹:低カルシウム血症と高カルシウム血症. Modern Physician 8::397-400, 1988

• 7) 小岩文彦, 北岡建樹:低カルシウム血症と高カルシウム血症の対策. 臨床医18:28-32, 1992

• 8) 中川俊太郎ほか:Ca, P代謝異常. 日本臨牀 42 (秋期臨時増刊号):1018-1025, 1984

P.135 掲載の参考文献

• 1) Asakura, H. et al.:Changes in plasma levels of tissue-plasminogen activator/inhibitor complex and active plasminogen activator inhibitor in patients with disseminated intravascular coagulation. Am. J. Hematol. 36:176-183, 1991
  pubmed

• 2) 青木延雄, 長谷川淳:DIC診断基準の「診断のための補助的検査成績, 所見」の項の改訂について. 厚生省特定疾患, 血液凝固異常症調査研究班昭和62年度研究報告書 (青木延雄編). 1988, pp.37-41

• 3) Asakura, H. et al.:The course of disseminated intravascular coagulation is predicted by changes in thrombin-antithrombin III complex level-Is there any difference between treatment with standard heparin or low-molecular-weight heparin? Blood Coag. Fibrinol. 2:623-627, 1991
  pubmed

• 4) 松田保:血管内凝固症候群 (DIC). 臨床血液17:1139-1152, 1976

[V] 進行・末期癌のPalliative Surgery

P.145 掲載の参考文献

• 1) 島津久明:癌の palliative therapy:Editorial. 臨外46:411, 1991

• 2) Twycross, R. G.:Hospice care reserving the balance in medicine. J. Royal. Soc. Med. 73:475-481,1978

• 3) 白鳥常男, 中島祥介:切除不能癌患者に発生したイレウスの処置. 消化器外科8:1575-1581, 1985

• 4) 金子徹也, 角賢一, 前田連郎ほか:化学療法が著効を示しsecond look operationにより切除された進行胃癌の1例. 日消外会誌23:2274-2278, 1990

• 5) 古江尚:制吐剤とその臨床評価の問題点. 癌と化学療法19:294-301, 1992

• 6) Gunduz, N, Fisher, B. and Saffer, F. A.:Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res. 39:3861-3865, 1979

• 7) 草間悟:癌の時間学. 臨床腫瘍学. 南江堂, 東京, 1982, pp.129-156

• 8) 大腸癌研究会:臨床病理大腸癌取扱い規約. 金原出版, 東京, 1985

• 9) 日置紘士郎, 中根恭司, 広実伸郎ほか:消化器癌末期のイレウスに対する手術. 外治64:463-467, 1991

• 10) 大島明, 津熊秀明, 日山興彦ほか:がんの自然歴-がん対策展開のための疫学的研究. 病態生理1:921-926, 1982

• 11) Haruma, K., Suzuki, T., Tsuda, T. et al.:Evaluation of tumor growth rate in patients with early gastric carcinoma of the elevated type. Gastrointest. Radiol. 16:289-292, 1991
  pubmed

• 12) 中村恭一, 芦沢真六, 高田洋ほか:胃癌の成長曲線. 胃と腸13:89-92, 1978

• 13) 胃癌研究会:臨床病理胃癌取扱い規約. 金原出版, 東京, 1979

• 14) 高木弘, 渡辺正, 伊藤勝基:再発癌とその治療. 新外科学大系. 腫瘍の外科II. 中山書店, 東京, 1988, pp.191-220

• 15) 廣田映五, 板橋正幸, 原田守久ほか:大腸癌の病理 (形態と組織発生). 大腸癌診断治療の最近の進歩. へるす出版, 東京, 1983, pp.315-326

• 16) 高橋孝, 草間悟, 北條慶一ほか:Discussion:大腸癌のnatural history. 大腸癌診断治療の最近の進歩. へるす出版, 東京, 1983, pp.386-395

• 17) 上野雅資, 大田博俊, 関誠ほか:大腸癌肝移転の細胞核DNA量の意義-腫瘍の増大速度 (CEA倍加時間) との対比-日外会誌91:1817, 1990

• 18) 高橋豊, 磨伊正義, 草間悟:癌悪性度パラメーターとしての発育速度とその転移・再発の予知への応用-腫瘍マーカーダブリングタイムと半減期-. 日外会誌92回臨時増刊号, 1991, p.20

• 19) 高橋豊, 磨伊正義, 秋本龍一:胃癌肝転移症例のnatural historyよりみた検討. 日消外会誌 16:2067-2073, 1983

• 20) Glover, D. J. and Grick, J. H., 大柴三郎, 平田一郎訳:腫瘍疾患における緊急合併症および特殊合併症. 上大静脈症候群. Medical Oncology. IV. Supportive Care. 同文書院, 東京, 1988, pp.1226-1229

• 21) 曽我淳, 鈴木力, 斉藤六温ほか:再発胃癌の治療-再切除例を中心に. 手術35:985-988, 1981

• 22) 小島治, 高橋俊雄:進行癌によるイレウスの治療. 外科49:1412-1415, 1987

• 23) 秋山守文, 水島康博, 伝野隆一:腸閉塞症におけるイレウス管の有用性. 日救急医誌2:351, 1991

• 24) 石川邦嗣:QOL 評価法の比較検討. 癌とQuality of Life. ライフ・サイエンス, 東京, 1991, pp.44-56

• 25) 佐々木聖子:Palliative surgeryとして人工肛門造設術を施行した進行・末期癌患者の周術期看護. Ope Nursing 6:784-791, 1991

• 26) 船曳孝彦, 落合正宏:膵頭部癌における胆道消化管通過障害. 臨外46:439-447, 1991

• 27) 藤井大吾, 有山襄, 須山正文ほか:経皮経肝胆道内痩術 (PTBE) による閉塞性黄疸を呈した切除不能膵癌の治療成績. 膵臓3:43-44, 1988

• 28) 吉田俊-, 清田啓介, 向井秀一ほか:内視鏡的逆行性胆管ドレナージ法 (ERBD) の臨床的評価-経皮経肝胆管ドレナージ法 (PTBD) との対比において, 日消誌82:638-647, 1985

• 29) Geenen, J. E and Venu, R. P.:Endoscopic management of biliary tract obstruction. Techniques in therapeutic endoscopy. Gower Medical Publishing. New York/London, 1992, C. 8

• 30) 鈴木太:手術に関連する痛みとその制御法. 日臨外会誌52:1393-1404, 1991

• 31) 市橋真理子, 佐々木聖子, 佐藤英子:症状コントロールとしてのストーマ造設が奏効した2例. 日本ストーマ学会誌7:96, 1991

• 32) 岸本弘之, 梶谷真司, 川角博規ほか:切除不能幽門側胃癌に対する空置的胃切離術の検討. 島根医学7:1027-1030, 1987

• 33) 吉川時弘, 栗根康行, 北村正次ほか:幽門狭窄症状を伴なう切除不能胃癌に対する空置的胃空腸吻合術の検討. 日消外会誌20:1431, 1987

• 34) 星川剛, 戸塚守夫, 北川一彦ほか:切除不能胃癌の検討-空置的胃空腸吻合術と他術式との比較検討を中心にして-. 北外誌32:101-105, 1087

• 35) Phillips, G. D. and Cousins, M. F., 花岡一雄訳:疼痛の神経学的機構と疼痛, 不安, 睡眠の関連性. 急性痛のマネジメント. メディカル・サイエンス・インターナショナル, 東京, 1987, pp.19-46

• 36) 秋山守文, 石谷邦彦:癌のパリアティブ・ケアにおける薬物療法の知恵:不安. 最新医学46:2464-2466, 1991

[VI] QOLからみた進行癌の化学療法

P.153 掲載の参考文献

• 1) DeWys, W. D., Begg, C., Lavin, P. T. et al.:Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69:491-497, 1980
  pubmed

• 2) DeWys, W. D., Begg, C., Band, P. et al.:The impact of malnutrition on treatment results in breast cancer. Cancer Treat. Rep. 65:87-91, 1981
  pubmed

• 3) Nixon, D. W., Moffitt, S. , Lawson, D. H. et al.:Total parenteral nutrition as an adjunct to chemotherapy of metastatic colorectal cancer. Cancer Treat.Rep. 65:121-128, 1981
  pubmed

• 4) Popp, M. B., Fisher, R. I., Simon, R. M. et al.:A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma:Effect on drug tolerance. Cancer Treat. Rep. 65:129-135, 1981
  pubmed

• 5) Popp, M. B., Morrison, S. D. and Brennan, M. F:Total parenteral nutrition in a methylcholanthrene-induced rat sarcoma model. Cancer Treat. Rep. 65:137-143, 1981

• 6) 川上正舒, 早田邦康:癌悪液質とサイトカイン-TNFと代謝- . Biotherapy 6:1230-1236, 1982

• 7) 中原和郎:生化学的癌研究の展望と考察. 癌の生化学. 医学書院, 東京, 1960, pp.1-21

• 8) 石塚秀夫, 田中裕:5'-DFURによる癌悪液質の代謝改善. 癌治療と宿主2:61-68, 1990

• 9) Tanaka, Y., Eda, H., Fujimoto, K. et al.:Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res. 50:4528-4532, 1990

P.159 掲載の参考文献

• 1) Ishitsuka, H. et al.:Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluorouridine. Gann 71:112-123, 1980
  pubmed

• 2) Kono, A. et al.:Activation of 5'-deoxy-5-fluorouridine by thymidine phosphorylase in human tumors. Chem. Pharm. Bull. 31:175-178, 1983
  pubmed

• 3) 三輪昌敬ほか:担癌動物および癌患者における正常および腫瘍組織のピリミジンヌクレオシドホスホリラーゼ活性と5'-DFURの5-FUへの変換. 癌と化学療法14:2924-2929, 1987

• 4) Tanaka, Y. et al.:Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Research 50:4528-4532, 1990

• 5) 石塚秀夫ほか:5'-DFURによる癌悪液質の代謝改善. 癌治療と宿主2:61-68, 1990

• 6) 石川徹:5'-DFURの移転抑制効果. 癌治療と宿主4:219-224, 1992

• 7) 仁井谷久暢ほか:5'-deoxy-5-fluorouridine (5'-DFUR) の各種悪性腫瘍に対する第2相多施設共同研究. 癌と化学療法12:2044-2051, 1985

• 8) 田口鐵男:5'-DFUR (doxifluridine). 癌と化学療法14:2235-2243, 1987

• 9) 馬島尚:抗癌剤投与に伴う免疫機能の低下. Mebio 5:71-76, 1988

• 10) 田口鐵男ほか:レンチナンphase IIIの遠隔成績. 癌と化学療法12:366-378, 1985

• 11) 藤本香ほか:癌悪液質発症マウスにおける5'-DFURの延命効果の解析. 日本癌学会総会記事 (第49回), 1990

• 12) Dewys, W. D. et al.:Prognostic effect of Weight loss prior to chemotherapy in cancer Patients. Am. J. Med. 69:491-497, 1980
  pubmed

P.168 掲載の参考文献

• 1) Theologides, A.:Pathogenesis of cachexia in cancer. Cancer 29:484-488, 1972
  pubmed

• 2) Norton, J. A., Peacock, J. L. and Morrison, S. D.:Cancer cachexia. CRC. Crit. Rev. Oncol. Hematol. 7:289-327, 1987

• 3) DeWys, W. D., Begg, C., Lavin, P. T. et al.:Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am. J. Med. 69:491-497, 1980
  pubmed

• 4) DeWys, W. D., Begg, C., Band, P. et al.:The impact of malnutrition on treatment results in breast cancer. Cancer Txeat. Rep. 65 (Suppl. 5):87-91, 1981

• 5) Corbett, T. H., Griswold, D. P. Jr., Roberts, B. J. et al.:Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 35:2434-2439, 1975

• 6) Tanaka, Y., Eda, H. Tanaka, T. et al.:Experimental cancer cachexia induced by trallsplantable colon 26 adenocarcinoma in mice. Cancer Res. 50:2290-2295, 1990
  pubmed

• 7) 藤本香, 田村澄江, 松本武久ほか:マウス結腸癌26由来の悪液質誘導株, 非誘導株の比較. 日本癌学会総会記事 (第51回), 1992

• 8) 藤本香, 入沢美香, 石田雅子ほか:癌悪液質を発症したヒト癌移植ヌードマウスにおける5'-DFURの悪液質改善効果. 日本癌学会総会記事 (第50回), 1991, p.2283

• 9) Tanaka, Y., Eda, H., Fujimoto, K. et al.:Anticachectic activity of 5'-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res. 50:4528-4532, 1990

• 10) Bertini, R., Bianchi, M., Villa, P. et al.:Depression of liver drug metabolism and increase in plasma fibrinogen by interleukin 1 and tumor necrosis factor:a comparison with lylnphotoxin and interferon. Int. J. Immunophamacol. 10:525-530, 1988

• 11) Marinkovic, S., Jahreis, G. P., Wong, G. G. et al.:IL-6 modulates the synthes is of a specific set of acute phase plasma proteins in vivo. J. Immunol. 142:808-812, 1989

• 12) Moldawer, L. L, Georgieff, M. and Lundholm, K.:Interleukin 1, tumor necrosis factor-a (cachectin) and the pathogenesis of cancer cachexia. Clin. Physiol. 7:263-274, 1987
  pubmed

• 13) Langstein, H. N. and Norton, J. A.:Mechanisms of cancer cachexia. Nzttri. Cancer 5:103-123, 1991
  pubmed

• 14) Eda, H., Tanaka, Y. and Ishitsuka, H.:5'-deoxy-5-fluorouridine improved cachexia by mechanism independent of its antiprolifer-ative action in colon 26 carcinoma-bearing mice. Cancer Chemother. Pharmacol. 29:1-6 1991

• 15) Tanaka, Y., Tanaka, T. and Ishitsuka, H.:Antitumor activity of indomethacin in mice bearing advanced colon 26 carcinoma compared with those with early transplants. Cancer,Res. 49:5935-5939, 1989
  pubmed

• 16) 田村澄江, 藤本香, 森一茂ほか:癌悪液質におけるサイトカインの役割. 日本癌学会総会記事 (第51回), 1992

• 17) Mori, M., Yamaguchi, K, Honda, S. et al.:Cancer cachexia syndrome developed in nude mice bearing melanoma cells producing leukemia-inhibitory factor. Cancer Res. 51:6656-6659, 1991
  pubmed

• 18) Black, K., Garrett, I. R. Mundy, G. R. et al.:Chinese hamster ovarian cells transfected with the murine interleukin-6 gene cause hypercalcemia as well as cachexia, leukocytosis and thrombocytosis in tumor-bearing nude mice. Endocrinol. 128:2657-2659, 1991

• 19) Strassmann, G., Fong, M., Kenney, J. et al.:Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J. Clin. Invest. 89:1681-1684, 1992
  pubmed

• 20) Gearing, D. P., Comeau, M. R., Friend, D. J. et al.:The IL-6 signal transducer, gp 130:An oncostatin M receptor and affinity converter for the LIF receptor. Science 255:1434-1437, 1992

• 21) Strassmann, G., Jacob, C. O., Evans, R. et al.:Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J. Immunol. 148:3674-3678, 1992
  pubmed

• 22) Ishitsuka, H. Miwa, M., Takemoto, K. et al.:Role of uridine phosphorylase for antitumor activity of 5'-deoxy-5-fluoriuridine. Gann 71:112-123, 1980
  pubmed

• 23) Furukawa, T., Yoshimura, A., Sumizawa, T. et al.:Angiogenic factor. Nature 356:668, 1992
  pubmed

• 24) Eda, H., Fujimoto, K., Watanabe, S. et. al.:Cytokines induce uridine phosphorylase in murine colon 26 carcinoma cells and make them more susceptible to 5'-deoxy-5-fluorouridine. Jpn. J. Cancer Res., in press

• 25) Eda, H., Fujimoto, K., Watanabe, S. et al.:Cytokines induce thymidine phosphorylase in tumor cells and make them more susceptibleto 5'-deoxy-5-fluorouridine, 投稿中

P.176 掲載の参考文献

• 1) Coates, A. et al.:On the receiving end-patient perception of the side-effects of cancer chemotherapy. Eur. J. Cancer Clin. Oncol. 19:203-208, 1983

• 2) Joss, R. A., Brand, B. C., Buser, K. S. et al.:The symptomatic control of cytostatic drug-induced emesis. A recent history and review. Eur. J. Cancer 26 (Suppl. 1), S 2-S 8, 1990

• 3) 仁井谷久暢, 長谷川浩一, 栗山喬之ほか:抗悪性腫瘍剤による悪心, 嘔吐に対するGrani-setronの臨床評価 (第3報). コハク酸メチルプレドニゾロンナトリウムを対照としたrandomized crossover 比較試験. 臨床医薬6 (補):87-106, 1990

• 4) 古江尚, 太田和雄, 田口鐵男ほか:抗悪性腫瘍剤による悪心, 嘔吐に対するgranisetronの臨床評価. 臨床医薬6 (補), 63-86, 1990

• 5) Stefanek, M. E., Scheidler, V. R. and Fetting, J. H.:Anticipatory nausea and vomiting:Does it remain a significant clinical probrem? Cancer 62:2654-2657, 1988

• 6) Andrykowski, M. A., Jacobsen, P. B., Holland, J. C. et al.:Prevalence, predictors, and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer. Cancer 62:2607-2613, 1988
  pubmed

• 7) Seigel, L. J. and Longo, D. L.:The control of chemotherapy-induced emesis. Ann. Intern. Med. 95:352-359, 1981
  pubmed

• 8) Fischer, D. S. and Knobf, M. T.:The cancer chemotherapy handbook. Gastrointestinal toxicity. Year Book Medical Publishers, Chicago, 1989, pp.495-547

• 9) Leonard, R. C. F. and Soukop, M.:Antiemetics and cancer chemotherapy. Br. J. Cancer 61:349-350, 1990

• 10) Gralla, R. J., Itri, L. M., Pisko, S. E. et al.:Antiemetic efficacy of high-dose metoclopramide.:randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 305:905-909, 1981
  pubmed

• 11) Kris, M. G., Gralla, R. J., Tyson, L. B. et al.:Controlling delayed vomiting.:double-blind, randomized trial comparing placebo, dexamethasone alone, alld metoclopramide plus dexamethasone in patients receiving cisplatin. J. Clin. Oncol. 7:108-114, 1989

• 12) Hamik, A. and Perouka, S. J.:Differential interactions of traditional and novel antiemetics with dopamine D2 and 5-hydroxytriptamine 3 receptors. Cancer Chemother. Pharmacol. 24:307-310, 1989

• 13) Hesketh, P. J. and Gandara, D. R.:Serotonin antagonists:anew class of antiemetic agents. J. Natl. Cancer lnst. 83:613-620, 1991

• 14) Tabona, M. V.:An overview on the use of granisetron in the treatment of emesis assocoated with cytostatic chemotherapy. Eur. J. Cancer 26 (Suppl. 1):S 37-S 41, 1990

• 15) Goddard, P. M., Jones, M., Pollard, L. A. et al.:The 5-HT3 antagonist, BRL does not compromise the efficacy of cisplatin in tumor-bearing mice. Cancer Chemother. Pharmacol. 25:377-379, 1990

• 16) Morrow, G. R:The assessment of nausea and vomiting.:past problems, current issues, and suggestions for future research. Cancer 53:2267-2278, 1984
  pubmed

• 17) Gralla, R. J.:Antiemetic treatment. Eur. J. Cancer 21:155-157, 1985

• 18) Morrow, G. R., Black, P. M, and Dudgeon, D. J.:Advances in date assessment. Application to the etiology of nausea reported during chemotherapy, concerns about significance testing, and opportunities in clinical trials. Cancer 67:780-787, 1991

• 19) 古江尚:制吐剤のその臨床評価の問題点. 癌と化学療法19:294-301, 1992

• 20) Soukop, M. et al.:Emesis control and quality of life during repeated chemotherapy for breast cancer. Ondansetron satellite symposium. Fortezza da Basso, Florence, Italy Abstract book, 1991, pp.34-40

• 21) 仁井谷久暢, 太田和雄, 田口鐵男ほか:抗悪性腫瘍剤による悪心, 嘔吐に対する Y-25130 注射剤の臨床評価. プラセボを対照とする多施設二重盲検比較試験. 薬理と治療20:173-190, 1992

P.183 掲載の参考文献

• 1) Browder, A. A., Hoff, J. A. and Petersdorf, R. G:The significance of fever in neoplastic disease. Ann. In tern. Med. 55:932-942, 1961

• 2) The EORTC International Antimicrobial Therapy Cooperative Group:Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytepenia. N. Engl. J. Med. 317:1692-1698, 1987

• 3) 太田和雄, 有吉寛, 福岡正博ほか:肺癌化学療法による好中球減少に対する Recombinant human G-CSF (rG-CSF注) の臨床検討. 癌と化学療法17:65-71, 1990

• 4) Crawford, J., Ozer, H., Stoller, R. et al.:Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N, Engl. J. Med. 325:164-170, 1991
  pubmed

[VII] 癌悪液質の栄養管理

P.191 掲載の参考文献

• 1) Rhoads, J. E. and Alexander, C. E:Nutritional problems of surgical patients. Ann. NY. Acad. Sci. 63:268-275, 1955
  pubmed

• 2) Blackburn, G. L, Maini, B. S. and Pierce. J.:Nutrition in the critically ill patient. Anesthesiology 47:181-194, 1977

• 3) Lange, K. O. and Brozek, J.:A new model for skinfold caliper. Am. J. Phys. Anthropol. 19:98, 1961

• 4) Vatistas, S. and Hornsey, S.:Radiation-induced protein loss into the gastrointestinal tract. Br. J. Radiol. 39:547-550, 1966
  pubmed

• 5) Cuthbertson, D. P. and Tilstone, W. J.:Metabolism during the postinjury period. Adv. Clin. Chem. 12:1-55, 1969

• 6) Viteri, F. E. and Alvarado, J.:The creatinine height index:its use in the estimation of the degree of protein depletion and repletion in protein-calorie malnourished children. Pediatrics 46:696-706, 1970
  pubmed

• 7) Jeejeebhoy, K. N, Bruce-Robertson, A. and Ho, J. et al.:The comparative effects of nutritional and hormonal factors on the synthesis of albumin, fibrinogen and transferrin. Ciba Foundation Symposium 9. In:Protein turnover, ed. by McFarlane, A. J., Amsterdam:Assqciated Scientific Publishers, 1973, pp.217-247

• 8) Sokal, J. E:Measurement of delayed skin-test responses. N. Engl. J. Med. 293:501-502, 1975
  pubmed

• 9) Slade, M. S., Simmins, R. L. and Uunis, E. et al.:Immunodepression after major surgery in normal patients. Surgery 78:363-372, 1975

• 10) Fleck, A.:Injury and plasma proteins. In:Metabolism and the response to inlury. Wilkinson, A. W., Cuthing Co., Ltd., 1976, pp.229-236

• 11) Ohuma, T. and Holland, J. F.:Nutritional consequences of cancer, chemotherapy and immunotherapy. Cancer Res. 37:2395-2406, 1977

• 12) Meakins, J. L, McLean, A. P. H. and Kelly, R. et al.:Delayed hypersensitivity and neutrophil chemotaxis:Effect of trauma. J. Trauma. 18:240-247, 1978

• 13) Harvey, K. B., Ruggiero, J. A. and Regan, C. S. et al.:Hospital morbidity-mortality risk factors using nutritional asessment. Clin. Res. 26:581A,1978

• 14) Pietsch, J. B. and Meakins, J. L:Predicting infection in surgical patients. Surg. Clin. North Am. 59:185-197, 1979
  pubmed

• 15) Reinhardt, G. F, Mycofski, J. W. and Wilkens, D. B. et al.:Incidence and mortality of hypoalbuminemic patients and hospitalized veterans. IPEN 4:357-359, 1980

• 16) Lewis, R. T. and Klein, H.:Risk factors in post-operative sepsis:significance of preoperative lymphocytopenia. J. Surg. Res. 26:365-370, 1980

• 17) Buzby. G. P., Mullen, J. L., Matthews, D. C. et al.:Prognostic nutritional index in gastrointestinal surgery. Am. J. Surg. 139:160-170, 1980
  pubmed

• 18) Daly, J. M., Dudrick, S. J. and Copeland, E. M.:Effect on delayed cutaneous hypersensitivity in cancer patients. Ann. Surg. 192:587-592, 1980
  pubmed

• 19) Harvey, K. B. , Moldawer, H. L. and Bistrian, B. R. et al.:Biological measurements for the formation of a hospital prognostic index. Am. J. Clin. Nutr. 34:2013-2022, 1981

• 20) 小野寺時夫, 五関謹秀:進行消化器癌患者の栄養状態と抗癌療法時の合併症発生頻度との関係. 日本臨床外科学会誌,7:60-64, 1987

P.199 掲載の参考文献

• 1) 近藤芳夫ほか (編):癌治療と栄養. 講談社, 東京, 1980

• 2) Rivlin, R. S. et al.:Nutrition and cancer. Am. J.Med. 75:843-853, 1983
  pubmed

• 3) Blackburn, G. L. et al.:J. Parenteral. Enteral. Nutr. 1:11, 1977

• 4) 佐藤博, 小越章平 (編):臨床外科栄養. 医学書院, 東京, 1979

• 5) 小越章平ほか:経腸的高カロリー栄養法の基礎と臨床. 成分栄養法 (佐藤博編). 南江堂, 東京, 1981

• 6) 真島吉也ほか:経管栄養の代謝管理. 医学のあゆみ125:878-887, 1983

• 7) 小越章平ほか:図解高カロリー輸液-安全な中心静脈栄養法 (佐藤博編). 医学書院, 東京, 1976

• 8) 丸山明則ほか:高カロリー輸液における電解質代謝. 内科50:643-650, 1982

• 9) 樫村博正, 福富久之:癌の合併症対策-栄養障害及び消化器機能障害. 日本臨牀47増刊号癌治療学 (下):731-737, 1989

P.206 掲載の参考文献

• 1) 谷村弘, 山上裕機:癌患者と栄養・輸液. 外科治療64:99-1O3, 1991

• 2) 谷村弘, 青木洋三, 竹井信夫ほか:栄養アセスメントと治療計画. 外科治療60:695-699, 1989

• 3) 標葉隆三郎, 西平哲郎, 森昌造:進行, 末期癌患者の栄養管理. 癌治療と宿主1:59-64, 1989

• 4) 平松義文, 山本政勝, 中根恭司ほか:癌患者の栄養管理. 癌患者と対症療法1:83-89, 1989

• 5) Shaw, J. H. F. and Wolfe, R. R.:Glucose and urea kinetics in patients with early and advanced gastrointestinal cancer:the response to glucose infusion, parenteral feeding, and surgical resection. Surgery 101:181-191, 1987

• 6) Eden, E, Edstrom, S., Bennegard, K. et al.:Glucose flux in relation to energy expenditure in malnourished patients with and without cancer during periods of fasting and feeding. Cancer Res. 44:1717-1724, 1984

• 7) Lundholm, K., Holm, G. and Schersten, T.:Insulin resistant in patients with cancer. Cancer Res. 38:4665-4670, 1978
  pubmed

• 8) 大柳治正:新しい高カロリー輸液用基本液の代謝に対する研究-手術侵襲モデル動物に静脈内投与された糖質配合比の異なるグルコース, フルクトース, キシリトース製剤の血中濃度変化ならびに排泄について.JPEN 6:557-570, 1985

• 9) Eden, E., Ekman, L, Lindmark, L. et al.:Whole body tyrosine flux in relation to energy expenditure in weight-losing cancer patients. Metabolism 33:1020-1027, 1984
  pubmed

• 10) Carmichael, M. J., Clague, M. B., Kier, M. J. et al..:Whole body protein turnover, synthesis and breakdown in patients with colorectal carcinoma. Br. H. Surg 67:736-769, 1980

• 11) 標葉隆三郎, 西平哲郎, 森昌造:癌悪液質と栄養管理. 癌治療と宿主2:71-76, 1990

• 12) Hunter, D. C, Weintraub, M., Blackburn, G. L. et al.:Branched chain amino acid as the protein component of parenteral nutrition in cancer cachexia. Br. J. Surg. 76:149-153, 1989
  pubmed

• 13) Kawamura, I., Sato, H., Ogoshi, S. et al.:Use of intravenous branched chain amino acid enriched diet in the tumor-bearing rat. Jpn. J. Surg. 15:471-476, 1985
  pubmed

• 14) 竹下俊文:担癌生体に対する高分岐鎖アミノ酸高カロリー輸液の基礎研究. 外科と代謝・栄養 19:126-137, 1985

• 15) Wendrop, R. I. C, Krause, R. and von Meyen-feldt, M. F:Cancer cachexia and its nutritional implications. Br. J. Surg. 70:352-355, 1983

• 16) 為定良行:担癌ラットTPNにおけるBCAA-richアミノ酸輸液の検討. 外科と代謝・栄養26:138-150, 1992

• 17) 今井圓裕, 野口民夫, 田中武彦:癌細胞の代謝系の変動-癌細胞における酵素偏倚について. 栄養-評価と治療9:135-141, 1992

• 18) Reynolds, J. V., Thom, A. K., Daly, J. M. et al.:Arginine, protein malnutrition and cancer. J. Surg. Res. 45:513-522, 1988

• 19) Barbul, A.:Arginine;Biochemistry, physiology, and therapeutic implications. JPEN 10:227-238, 1986
  pubmed

• 20) 五関謹秀, 山崎繁, 遠藤光夫:いわゆるメチオニンインバランス (RT) 療法と抗癌剤の併用療法の効果-進行癌患者におけるQuality of lifeの面から. Karkinos 3:931-937, 1990

• 21) 吉岡一夫, 嵩原裕夫, 古味信彦:New amino acid imbalanced solutionを用いたTPNの腫瘍および宿主への影響. 四国医誌47:27-36, 1991

• 22) Hansell, D. T., Davies, J. W. L. and Bruns, H. J. G:The relationship between resting energy expenditure and weight loss in benign and malignant disease. Ann. Surg. 203:240-245, 1986

• 23) Shaw, J. H. F. and Wolfe, R. R.:Fatty acid and glycerol kinetics in septic patients and in patients with gastrointestinal cancer:the response to glucose infusion and parenteral feeding. Ann. Surg. 205:368-376, 1987

• 24) Legaspi, A., Jeevanandam, M., Starnes, H. F. et al.:Whole body lipid and energy metabolism in the cancer patient. Metabolism 10:958-963, 1987
  pubmed

• 25) Edmonston, J. H.:Fatty acid metabolism in cancer patients. Cancer 19:277-280, 1966

• 26) 瀧藤克也, 谷村弘, 馬庭芳朗ほか:標識脂肪乳剤を用いた脂肪乳剤構成成分の体内動態. 外科と代謝・栄養26:131-137, 1992

• 27) Carpentier, Y. A.:Intravascular metabolism of fat emulsions:The Arvid Wretlind Lecture, ESPEN 1988. Clin. Nutr. 8:115-125, 1989
  pubmed

• 28) Nugent, K. M.:Intralipid effect on reticuloen-dotherial function. J. Leukocyte Biol. 36:123-132, 1984

• 29) Vlassara, H., Spiegel, R. J., Doval. D. S. et al.:Reduced plasma lipoprotein lipase activity in patients with malignancy associated weight loss. ,Horm. Metab. Res. 18:698-703, 1986

• 30) 馬庭芳朗, 谷村弘, 杉本恵洋ほか:中鎖脂肪酸トリグリセリド乳剤静注時の肝における脂質代謝に関する電子顕微鏡学的研究. 外科と代謝・栄養25:375-382, 1991

• 31) 谷村弘, 馬庭芳朗:脂肪-素材の導入と展開. 癌・免疫・栄養3:18-23, 1989

• 32) 標葉隆三郎:新しい栄養素材-脂肪 (MCTを中心に). 臨床外科47:459-464, 1992

• 33) 瀧藤克也, 谷村弘, 馬庭芳朗ほか:新しいリン脂質にて乳化した脂肪乳剤の血中消失速度と肝組織の電子顕微鏡的観察. 日本静脈経腸栄養会誌,6:94-97, 1991

• 34) 瀧藤克也:新しい乳化剤による脂肪乳剤の作成とその代謝に関する生化学的・形態的研究. 和歌山医学42:805-822, 1991

• 35) Dionigi, P., Dionigi, R., Prati, U et al.:Effect of Intralipid on some immunological parameters and leukocyte functions in patients with esophageal and gastric cancer. Clin. Nutr. 4:229-234, 1985
  pubmed

• 36) Mulligan, H. D. and Tisdale, M. J.:Effect of the lipid-lowering agent bezafibrate on tumour growth rate in vivo. Br. J. Cancer 64:1035-1038, 1991
  pubmed

• 37) Villa, M. L, Ferrario, E., Bergamasco, E. et al.:Reduced natural killer activity and IL-2 production in malnourished cancer patients. Br. J. Cancer 63:1010-1014, 1991
  pubmed

• 38) 谷村弘, 山上裕機, 馬庭芳朗ほか:癌と栄養管理, 経静脈栄養と経腸栄養. 癌治療と宿主3:15-23, 1991

• 39) Schepetkin, I. A., Cherdyntseva, N. V. Borunov, E. V. et al.:Decreased luminol-dependent chemiluminescence response of neutro-phils to recombinant human tumor necrosis factor in patients with gastric cancer. J. Cancer Res. Clin. Oncol. 117:172-174, 1991

• 40) 谷村弘, 山上裕機:癌治療における栄養投与の意義, 免疫. 栄養-評価と治療9:187-191, 1992

• 41) 赤毛義実, 竹山廣光, 由良二郎:癌と栄養, 脂肪と制癌効果. 栄養-評価と治療9:175-180, 1992

• 42) 真島吉也, 奥井勝二, 木村信良ほか:魚油を配合した脂肪乳剤TR-8030の外科領域における第三相比較臨床試験. JPEN 14:789-813, 1992

• 43) 岩佐正人, 小越章平, 韓相宗ほか:新しい栄養素材-核酸成分輸液. 臨床外科47:475-479, 1992

• 44) 谷村弘, 小林展章, 三木毅一郎:ワンパック高カロリー輸液. 臨牀看護10:2231-2241, 1984

• 45) 城戸良弘, 小川嘉誉, 小林貢ほか:脂肪乳剤を含むone pack高カロリー輸液の投与. JPEN 7:345-347, 1985

• 46) 谷村弘, 内山和久:家庭内栄養・輸液の問題点. 外科治療 64:491-495, 1991

• 47) Howard, I. and Michalek, A. V.:Home parenteral nutrition (HPN). Annu. Rev. Nutr 4:69-99, 1984

• 48) Hill, G. L:Massive enterectomy:Indications and management. World J. Surg. 9:833-841, 1985
  pubmed

• 49) Kemeny, M. M.:Liver lesions on hyperalimentation. J. Surg. Oncol. 35:82-85, 1987
  pubmed

P.215 掲載の参考文献

• 1) 大谷剛正, 桜本信一, 比企能樹:在宅癌化学療法の組織体制. 癌治療と宿主3:376-381, 1991

• 2) 大谷剛正, 桜本信一, 比企能樹:在宅癌治療のための院内体制. 在宅癌治療1:31-35, 1990

• 3) 上野聰一郎, 大谷剛正, 比企能樹:末期癌患者に対する在宅静脈栄養に関する検討. 北里医学 19:612-616, 1989

[VIII] QOLからみた癌の免疫化学療法

P.228 掲載の参考文献

• 1) 螺良英郎:癌患者におけるQOLについて思うこと. 癌治療と宿主3:230-231, 1991

• 2) Theologides, A.:Pathogenensis of cachexia in cancer. Cancer 29:484, 1972

• 3) Norton, J. A., Pearcock, J. L. and Morrison, S. D.:Cancer cachexia. CRC. Crit. Rev. Oncol. Hematol. 7:289, 1987

• 4) Anthony, H. K., Madsen, K. E., Mason, M. K. et al.:Arandomized study of intradermal BCG in patients with carcinoma of the bronchus. Cancer 42:1784-1792, 1985

• 5) 澄井俊彦, 木村寿成, 矢津剛ほか:膵癌に対するレンチナン療法の臨床的有用性-Quality of Lifeによる判定-. 腫瘍と感染3:23-28, 1990

• 6) 亀田千里, 赤沢修吾, 三好和夫ほか:無作為化比較試験によるレンチナンの臨床試験. Biotherapy 4:941-948, 1990

• 7) 石神博昭, 奥井勝二, 青木靖雄ほか:進行・再発胃癌に対するTegaful・レンチナン併用療法の臨床効果. Biotherapy 4:1195-1201, 1990

• 8) 江端俊彰, 戸塚守夫, 内野純一ほか:進行胃癌に対するレンチナンの臨床効果. Biotherapy 5:721-723, 1991

• 9) 石谷邦彦, 石川邦嗣, 近藤敦ほか:レンチナンによるQuality of Lifeの向上. 基礎と臨床24:271-278, 1990

• 10) 石谷邦彦, 石川邦嗣, 近藤敦ほか:レンチナンのQuality of Life向上効果について. 診療と新薬28:127-148, 1991

• 11) 石川邦嗣, 熊谷良司, 本多利雄ほか:進行・末期癌患者における OK-432による QOL の向上. Biotherapy 5:1344-1349, 1991

• 12) 門政男, 大島駿作:III・IV期肺腺癌に対する OK-432の臨床効果-多施設共同による無作為化比較試験-. 医学と薬学26:365-380, 1991

• 13) 清水哲郎:真実を知らせることとしての癌告知. 癌治療と宿主3:47-52, 1991

• 14) 石川邦嗣, 石谷邦彦:QOLの今日的概念. ターミナル・ケア2:227-231, 1992

• 15) Schipper, II.:Guideline and caveats for quality of life measurement in clinical practice and research. Oncology 4:51-57,1990

• 16) Donovan, K, Sanson-Fisher, R. W. and Redman, S.:Measuring quality of life in cancer patients. J. Clin. Oncol. 7:959-968, 1989
  pubmed

• 17) 栗原稔, 清水広之, 坪井康次ほか:癌薬物治療におけるQOL評価のための調査項目の設定. Oncologia 25:131-137, 1992

• 18) 石川邦嗣, 近藤敦, 本多利雄ほか:進行癌患者のQOLの測定方法に関する研究. 癌治療と宿主2:115-122, 1990

• 19) 古江尚, 服部孝男, 田口鐵男:レンチナンのPhase III Studyの遠隔成績. 癌と化学療法12:366-378, 1985

• 20) 富永純男, 靖部博康, 八尾英一郎ほか:胃癌を中心としたレンチナンの使用経験-NRI (Nutritional Risk Index) 値変動を中心として-. Karkinos 4:1399-1408, 1991

• 21) 粟生修司, 馬静恰, 堀哲郎:ラット摂食行動および血中カルシウムレベルにおよぼすレンチナンの効果. Biotherapy 5:1728-1731, 1991

• 22) 石川邦嗣, 岸明彦:QOLからみた癌のBRM療法. Biotherapy 6:1057-1064, 1992

• 23) 生越喬二:免疫化学療法とQOLの向上. Pharma Medica 7:23-28, 1989

• 24) Rubin, L. A., Boutin, B., Nelson, D. et al.:Soluble interleukin 2 receptor are released form activated human lymphoid cells in vitro. J Immunol. 135:3172-3177, 1985

• 25) Reske-kunz, A. B., Osawa, II., Diamtstein, T. et al.:Soluble interleukin 2 receptors are released by long term cultured insulin-specific T cells transiently after contact with antigen. J. Immunol. 138:192-196, 1987

• 26) 折田薫三:癌免疫療法の理論的根拠. Current Therapy 8:352-357, 1990

• 27) Jacques, Y., Mauff, B. L. and Soulillou, J.:A soluble interleukin-2 recepter produced by a nornial alloreactive human T cell clone binds interleukin 2 with low affinity. J. Immunol. 139:2308, 1987

• 28) Lai, K. N, Ho, S., Leung, J. C. K. et al.:Soluble interleukin 2 receptors in patients with nasopharyngeal carcinoma. Cancer 67:2180-2185, 1991

• 29) Poulakis, N, Sarandakon, A., Rizos, D. et al:Soluble interleukin 2 receptors and other maker in primary lung cancer. Cancer 68:1045-1049, 1991

• 30) Lissoni, P., Barni, S., Rovelli, F. et al.:Correlation of serum interleukin-2 1evels, soluble interleukin-2 receptors and T lymphocyte subsets in cancer patients. Tumori 71:14-17, 1990

• 31) 後藤田栄樹:癌の免疫化学療法. 免疫腫瘍学入門 (小林博編), 蟹書房, 東京, 1981, pp.304-314

• 32) 藤田道也:神経系と免疫系の関連-とくに精神と免疫機能との関連について. 生体の科学42:2-5, 1991

• 33) Kruger, T. E, Smith, L. R, Harbour, D. V. et al.:Thyrotropin:an endogenous regulator of the in vitro immune response. J. Immunol. 147:744, 1989

• 34) 漆崎一朗, 石川邦嗣, 石谷邦彦:神経・内分泌・免疫系の相関からみた癌のBRM療法-QOLの改善の意味するもの-. Biotherapy 6:1-8, 1992

• 35) 飴島慎吾, 星野孝, 宮保進:BRMの内分泌機能とQOLへの効果-特にOK-432について-. Biotherapy 6:1041-1051, 1992

• 36) 石塚秀夫, 田中裕:5'-DFURによる癌悪液質の代謝改善. 癌治療と宿主2:6168, 1990

• 37) 羽室純爾ほか:胆癌末期における免疫化学療法適用の意義-CY, レンチナン, IL-2, 三者併用療法開発の試み-. Biotherapy 5:240-245, 1991

• 38) 細川真澄男:BRM治療効果増強の戦略としての癌化学療法. Biotherapy 5:196-1968, 1991